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1.	  Abstract	  	  
Background:	   Alzheimer’s	   disease	   (AD)	   is	   the	  most	   common	   cause	   of	   dementia	   in	   the	  world.	  This	  disease	  is	  characterized	  by	  neuronal	  degeneration	  as	  well	  as	  the	  accumulation	  of	  abnormal	  proteins.	   An	   increase	   of	   evidences	   shows	   that	   the	   disease	   is	   also	   accompanied	   by	   a	   reactive	  gliosis,	  which	  allows	  advancing	  the	  hypothesis	  that	  an	  inflammatory	  process	  occurs	  in	  the	  brain	  through	   an	   increase	   in	   microglia	   and	   astrocytes	   density.	   These	   cells	   respond	   dynamically	   to	  neurodegenerative	  lesions	  inducing	  a	  local	  activation	  of	  immune	  components	  and	  acquiring	  the	  ability	   to	   secrete	   pro-­‐inflammatory	   cytokines	   such	   as	   IL-­‐1β	   and	   TNF-­‐α	   thereby	   triggering	   an	  immune	  cascade.	  It	  is	  assumed	  that	  chronic	  inflammatory	  processes	  in	  specific	  areas	  of	  the	  brain	  such	   as	   the	   entorhinal	   and	   frontal	   cortex	   could	   contribute	   to	   the	   worsening	   of	   the	   clinical	  symptoms	  of	   the	  disease.	  Moreover,	   some	  studies	  have	   suggested	   that	   the	  use	  of	  nonsteroidal	  anti-­‐inflammatory	  drugs	  (NSAIDs)	  may	  help	  to	  curb	  or	  even	  prevent	  AD.	  
Method:	   In	   order	   to	   understand	   the	   relationship	   between	   inflammatory	   processes	   and	  Alzheimer’s	  disease,	  the	  inflammatory	  changes	  were	  investigated	  in	  human	  brain	  tissues	  of	  the	  entorhinal	   and	   the	   frontal	   cortex	   from	   control	   and	   AD	   subjects	   by	   using	   one-­‐dimensional	  electrophoresis	   and	   immunostaining	   combined	   with	   chemiluminescence.	   A	   polyclonal	   GFAP	  antibody	  was	  used	  to	  detect	  the	  reactive	  astrogliosis,	  a	  monoclonal	  AD2	  antibody	  to	  evaluate	  the	  accumulation	   of	   pathological	   tau	   protein	   and	   a	  monoclonal	   β-­‐amyloid	   antibody,	   which	   reacts	  with	   the	   component	   of	   senile	   plaques.	   Three	   antibodies	   were	   used	   to	   detect	   specific	  inflammatory	   proteins,	   a	   monoclonal	   TNF-­‐α	   antibody,	   a	   monoclonal	   IL-­‐1β	   antibody	   and	   a	  monoclonal	   NF-­‐κB	   antibody.	   Quantitative	   and	   statistical	   analyses	   were	   then	   performed	   to	  compare	   the	   respective	   concentrations	   of	   these	   proteins	   in	   the	   two	   brain	   regions	   between	   a	  control	  group	  and	  moderate	  and	  severe	  Alzheimer’s	  disease	  cases.	  
Results:	   The	   results	   highlighted	   a	   disparity	   in	   the	   pathological	   accumulation	   of	   tau	   and	   β-­‐amyloid	  proteins	  not	  only	  according	  to	  the	  stage	  of	  the	  disease	  but	  also	  depending	  on	  the	  brain	  region.	   It	   also	   appears	   that	   the	   reactive	   astrogliosis	   and	   the	   inflammatory	  processes,	   found	   in	  significant	   quantities	   at	   the	   beginning	   of	   AD,	   do	   not	   persist	   indefinitely	   and	   that	   there	   is	   a	  decrease	  of	  these	  proteins	  when	  the	  disease	  reaches	  an	  advanced	  stage.	  	  
Conclusions:	  Alzheimer’s	  disease	  is	  marked	  by	  the	  presence	  of	  a	  significant	  amount	  of	  glial	  cells	  as	  well	  as	  a	  high	  density	  of	   inflammatory	  molecules.	  However,	   these	  components	  are	   involved	  early	  in	  the	  development	  of	  the	  disease	  and	  do	  not	  seem	  to	  be	  correlated	  with	  the	  worsening	  of	  the	   cognitive	   decline.	   Therapies	   focused	   on	   inflammatory	   processes,	   as	   for	   example	   NSAIDs,	  should	  then	  be	  administered	  as	  soon	  as	  possible	  when	  the	  symptoms	  are	  still	  mild	  or	  even	  not	  yet	  clinically	  diagnosed.	  New	  diagnostic	  techniques	  are	  therefore	  necessary	  to	  detect	  the	  disease	  in	   the	  very	  early	  stages	  and	  the	  development	  of	   targeted	  treatments	  remains	  one	  of	   the	  major	  challenges	  of	  current	  research	  about	  Alzheimer’s	  disease.	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2.	  Introduction	  	  	  As	   longevity	   increases,	  the	   age-­‐related	   diseases	   become	   more	   prevalent	   and	   particularly	  disorders	  of	  cognition.	  Best-­‐known	  under	  the	  term	  of	  dementia	  this	  condition	  can	  be	  caused	  by	  a	  set	  of	  diseases	  and	  traumas	  that	  affect	  the	  brain	  as	  for	  example	  neurodegenerative	  disorders	  or	  strokes.	  In	  2012,	  according	  to	  the	  Swiss	  Alzheimer’s	  Association	  estimations,	  approximately	  8%	  of	   the	  people	  over	  65	  and	  more	   than	  30%	  of	   those	  over	  90	   live	  with	  a	  dementia	   [1,	  2].	  As	   the	  number	  of	  elders	  in	  our	  society	  increases,	  dementia	  has	  become	  a	  major	  concern	  for	  the	  aging	  population	  and	  will	  become	  one	  of	   the	  biggest	   challenges	  over	   the	  next	   thirty	  years.	   It	   is	  now	  estimated	   that	   about	  110’000	  people	   live	  with	  dementia	   in	   Switzerland	  and	   the	  prevalence	  of	  this	  condition	  is	  expected	  to	  triple	  by	  2050	  [3,	  4].	  	  According	   to	   the	  World	  Health	  Association,	   dementia	   refers	   to	   a	   syndrome,	  usually	   of	   chronic	  course	   in	   which	   there	   is	   a	   memory	   disorder	   associated	   with	   at	   least	   one	   other	   cognitive	  impairment	   such	   as	   attention,	   language,	   visuospatial	   skills	   or	   problem	   solving	   [1].	   These	  changes	  must	  be	  of	  sufficient	  severity	   to	  affect	  daily	   functional	  activities	  and	  are	  beyond	  what	  should	  be	  observed	  during	  normal	   aging	   [4].	   The	   clinical	  manifestation	  of	   dementia	  may	  vary	  according	   to	   the	   degree	   of	   severity	   of	   the	   disease.	   The	   signs	   and	   symptoms	   of	   dementia	   can	  generally	  be	   classified	   into	   three	   stages	   [4,	   5,	   6]:	   1)	  The	   first	   stage	   in	  which	   the	  disease	  often	  goes	  unnoticed	   is	  characterized	  by	  a	  tendency	  to	   forget	  appointments	  or	  to	  get	   lost	   in	   familiar	  places.	  Symptoms	  usually	  appear	  gradually	  and	  patients	  and	  their	  relatives	  often	  consider	  these	  manifestations	  as	  a	  normal	  part	  of	  aging,	  which	  makes	  the	  diagnosis	  of	  dementia	  difficult	  as	  that	  moment.	  2)	  The	  second	  stage	  corresponds	  to	  a	  worsening	  of	  signs	  and	  symptoms.	  The	  patients	  suffer	   significant	   omissions	   regarding	   recent	   events	   or	   forget	   for	   example	   the	   names	   of	   their	  relatives	   or	   the	   names	   of	   very	   well	   known	   personalities	   such	   as	   presidents.	   There	   is	   also	   a	  greater	   difficulty	   with	   communication.	   3)	   The	   end-­‐stage	   of	   dementia	   is	   characterized	   by	   an	  almost	   total	  dependence	  and	   is	  marked	  by	  a	  strong	   inactivity.	  The	  memory	  problems	  are	  very	  important	   and	   the	   physical	   signs	   and	   symptoms	   become	  more	   evident.	   Symptoms	   can	   range	  from	  loss	  of	  consciousness	  of	  time	  and	  space	  to	  the	  difficulty	  to	  communicate	  and	  move.	  There	  are	  also	  behavioural	  changes	  with	  greater	  impulsivity	  and	  aggressiveness.	  Although	  dementia	  mainly	   affects	   the	   elderly	   it	   is	  not	   a	   condition	  of	  normal	   aging	  and	  always	  represents	  a	  pathological	  process.	  Unfortunately	  the	  current	  state	  of	  knowledge	  does	  not	  enable	  us	   to	   prevent,	   stop	   or	   cure	   this	   condition	   [1].	   However,	   different	   treatments	   contribute	   to	  improve	  the	  quality	  of	  life	  of	  these	  patients	  [1,	  4].	  	  	  Dementia	   requires	   a	  major	   commitment	   of	   the	   relatives	   but	   also	   of	   the	   institutions	   and	  other	  care	  services.	  This	  disease	  has	  indeed	  not	  only	  physical	  and	  psychological	  consequences	  but	  has	  also	  a	   significant	   impact	  on	  social	   and	  economic	  conditions	   [5].	   It	   is	  now	  considered	   the	   third	  leading	   cause	   of	  medico-­‐social	   dependencies	   after	   cardiovascular	   diseases	   and	   cancers	   [1,	   2].	  Therefore,	   it	   is	   important	   to	  make	  an	  early	  diagnosis	   in	  order	   to	  provide	   specific	   support	   and	  help	  improve	  the	  quality	  of	  life	  of	  the	  patients	  and	  their	  families.	  This	  could	  also	  help	  delay	  the	  institutionalization	  often	  necessary	  in	  the	  terminal	  state	  of	  the	  disease.	  	  There	  are	  many	  causes	  of	  dementia	   including	  Alzheimer’s	  disease,	   fronto-­‐temporal	  dementias,	  diffuse	   lewy-­‐body	   disease,	   vascular	   and	  mixed	   dementia	   [6].	   The	   final	   etiological	   diagnosis	   of	  cognitive	   disorders	   can	   only	   be	   confirmed	   by	   post-­‐mortem	   neuropathological	   analysis	   [5,	   7];	  however,	  clinical	  diagnosis	  can	  detect	  the	  presence	  of	  dementia	  with	  acceptable	  specificity	  and	  sensitivity	   [7].	   The	   clinical	   assessment	   of	   cognitive	   disorders	   is	   based	   on	   the	   definition	   of	  dementia	  according	  to	  the	  International	  Classification	  of	  Diseases:	  the	  CIM-­‐10	  [8]	  and	  the	  DSM-­‐IV	   TR	   [9].	   According	   to	   these	   classifications,	   the	   concept	   of	   dementia	   excludes	   an	   acute	  confusional	  state,	  a	  psychiatric	  disorder	  such	  as	  depression,	  only	  one	  single	  cognitive	  deficit	  and	  a	   mental	   retardation	   [8,	   9].	   The	   first	   step	   of	   the	   diagnosis	   is	   to	   collect	   a	   detailed	   history	   of	  symptoms	  and	  the	  rapidity	  of	  their	  progression.	  This	  history	  can	  be	  hold	  from	  the	  patient	  but	  an	  updated	  version	  of	  the	  family	  also	  plays	  a	  central	  role	  to	  clarify	  the	  exact	  course	  of	  the	  disease	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[4].	  This	  first	  evaluation	  may	  be	  facilitated	  by	  the	  use	  of	  standardized	  assessments	  tools	  such	  as	  the	   Informant	   Questionnaire	   on	   Cognitive	   Decline	   in	   the	   Elderly	   (IQCDE)	   [10];	   the	   Nurse’s	  Observation	  Scale	  for	  Geriatric	  Patients	  (NOSGER)	  [11];	  the	  Bayer-­‐Activities	  of	  Daily	  Living	  Scale	  (BADL)	   [12]	   and	   the	   Instrumental	  Activities	   of	  Daily	   Life	   Scale	   (IADL)	   [13].	  Additional	   testing	  may	  also	  be	  used	  such	  as	  the	  Mini	  Mental	  State	  Examination	  (MMSE)	  [7],	  the	  clock	  test	  [14],	  the	  Mementool	  [7]	  and	  the	  Mini	  Geriatric	  Depression	  Scale	  (GDS)	  [7].	  These	  screening	  tests	  do	  not	  allow	  a	  precise	  diagnosis	  but	   they	  highlight	   the	  probability	  of	  dementia	   and	  are	  good	   tools	   to	  assess	   the	   severity	   of	   the	   cognitive	   impairment.	   Thus,	   abnormal	   results	   to	   these	   tests	   should	  encourage	  pursuing	  further	  and	  specialized	  investigations	  [7].	  	  The	   next	   step	   is	   to	   clarify	   the	   etiologic	   entity	   suspected	   to	   be	   the	   cause	   of	   the	   cognitive	  impairment.	  The	  neuroradiological	   investigations	  of	   the	  brain	  are	  essential	   for	   the	  differential	  diagnosis	   [4,	   7].	   The	   magnetic	   resonance	   imaging	   (MRI)	   is	   the	   best	   technique	   to	   establish	   a	  diagnostic	  hypothesis	  mainly	  based	  on	  the	  exclusion	  of	  other	  conditions	  that	  can	  cause	  similar	  symptoms,	  such	  as	  a	  tumour	  for	  example	  [4].	  This	  approach	  also	  allows	  to	  assess	  the	  importance	  of	   vascular	   changes	   in	   the	   brain	   and	   to	   estimate	   brain	   atrophy	   [4].	   The	   diagnosis	   however	  generally	   remains	   a	   diagnosis	   based	   on	   probabilities	   and	   can	   only	   be	   confirmed	   on	   a	  neuropathological	  level.	  	  Among	  all	  the	  causes	  of	  dementia,	  Alzheimer's	  disease	  (AD)	  is	  by	  far	  the	  most	  common	  one	  and	  is	  believed	  to	  cause	  60	  to	  70%	  of	  all	  cases	  [1].	  Only	  probable	  clinical	  diagnosis	  of	  AD	  is	  currently	  available	  mainly	  based	  on	  the	  precise	  characterization	  of	  cognitive	  and	  behavioural	  deficits	  but	  there	   is	   unfortunately	   no	   absolute	   correlation	   between	   clinical	   signs	   and	   the	   underlying	  pathology	   [3].	   More	   over,	   other	   causes	   of	   dementia	   can	   also	   appear	   in	   addition	   of	   the	  characteristics	  of	  AD	  making	  more	  difficult	  the	  etiological	  diagnosis.	  That	  is	  why	  at	  present	  the	  ultimate	  and	  precise	  diagnosis	  of	  AD	  is	  not	  possible	  without	  the	  post-­‐mortem	  neuropathological	  confirmation	  [15].	  This	  study	  focuses	  on	  this	  very	  common	  type	  of	  dementia.	  
	  
	  
3.	  Alzheimer’s	  disease	  	  	  
3.1	  Clinics	  	  A	  German	  psychiatrist,	  Emil	  Kraepelin,	  first	  described	  the	  symptoms	  of	  this	  disease	  in	  the	  early	  1900s	  [16].	  It	  is	  however	  Alois	  Alzheimer,	  a	  German	  psychiatrist,	  neurologist	  and	  physician	  who	  discovered	  the	  neuropathological	  features	  underlying	  the	  disease	  [16].	  It	  was	  in	  1906	  that	  he	  discovered	  a	  peculiar	  disease	  in	  the	  cerebral	  cortex	  of	  August	  Deter,	  a	  woman	  who	  suffered	  memory,	  language	  and	  other	  psychological	  disorders	  [17].	  	  	  	  Alzheimer’s	   disease	   is	   clinically	   characterised	   by	   an	   amnesiac	   syndrome	   –	  with	   loss	   of	   short-­‐term	   and	   long-­‐term	   memory	   as	   well	   as	   episodic	   and	   semantic	   memory	   –	   associated	   with	   a	  deterioration	   of	   higher	   cognitive	   functions	   such	   as	   visual	   and	   spatial	   disorders	   as	   well	   as	  problems	   with	   reasoning	   or	   calculating	   difficulties	   [5,	   6,	   7].	   These	   troubles	   are	   the	   sign	   of	   a	  cortical	  involvement	  [5].	  	  A	   pre-­‐symptomatic	   state	   called	   mild	   cognitive	   impairment	   (MCI)	   is	   thought	   to	   be	   an	  intermediate	  state	  between	  normal	  cognition	  and	  dementia	  [18].	  MCI	  criteria	  typically	  include	  a	  measurable	  deficit	  in	  cognition	  in	  at	  least	  one	  domain	  but	  not	  fulfilling	  the	  criteria	  of	  dementia	  and	   having	   no	  major	   impact	   on	   activities	   of	   daily	   life	   [18,	   19].	   The	   exact	   distinction	   between	  normal	   aging	   and	  MCI	   is	   difficult	   in	   clinical	   practice	   because	   of	   their	   similarities.	   It	   is	   normal	  with	  aging	  to	  experience	  memory	  problems	  and	  other	  cognitive	  disorders	  but	  the	  concept	  of	  MCI	  was	  originally	  developed	  to	  highlight	  the	  memory	  impairment	  and	  its	  possible	  precursor	  status	  of	   AD.	   Petersen	   et	   al	   have	   actually	   highlighted	   the	   development	   of	   certain	   forms	   of	   cognitive	  impairment	  to	  a	  more	  advanced	  disease	  making	  the	  MCI	  a	  probable	  early	  onset	  of	  dementia	  [20].	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As	   for	   the	   other	   dementias,	   clinical	   diagnosis	   of	   Alzheimer's	   disease	   is	   based	   on	   a	   series	   of	  diagnostic	   criteria	   making	   it	   more	   or	   less	   probable	   or	   in	   some	   cases	   almost	   certain.	   It	   is	  recommended	  to	  use	  the	  diagnostic	  criteria	  for	  Alzheimer's	  disease	  according	  to	  the	  DSM-­‐IV-­‐TR	  [9]	  and	  the	  NINCDS-­‐ADRDA	  [21,	  22].	  These	  criteria	  are	  mainly	  based	  on	  the	  clinical	  symptoms	  of	  the	  disease	  affecting	  the	  cognitive	  functions	  but	  they	  also	  consider	  the	  somatic	  and	  psychiatric	  disorders,	  the	  personality	  and	  social	   interaction	  changes	  as	  well	  as	  the	  family	  problems.	  Based	  on	   the	   results	  of	   these	  evaluations	  and	  diagnostic	   criteria	   a	  probable	  diagnosis	  of	  Alzheimer's	  disease	  can	  be	  established.	  	  In	  the	  absence	  of	  biological	  or	  neuroimaging	  markers	  of	  AD,	  clinicians	  must	  rely	  on	  the	  clinical	  symptoms.	   The	   scales	   GDS9	   (Global	   Deterioration	   Scale)	   [23]	   and	   CDR10	   (Clinical	   Dementia	  Rating)	   [24]	   provide	   a	  multidimensional	   assessment	   of	   cognition,	   function	   and	  behaviour	   and	  thus	   generally	   allow	   specifying	   the	   stage	   of	   the	   disease.	   Three	   major	   clinical	   stages	   of	  Alzheimer's	   disease	   are	   defined	   [5,	   6,	   25]	   and	   are	   represented	   in	   the	   FIG.1	   below.	   The	   initial	  stage	  of	  the	  disease	  is	  marked	  by	  a	  greater	  intellectual	  passivity	  with	  a	   loss	  of	   interest	   in	  daily	  activities,	  a	  failure	  of	  memory	  and	  anomic	  aphasia	  characterized	  by	  a	  difficulty	  for	  the	  patient	  to	  find	   his	   words.	   The	   second	   stage	   of	   the	   disease	   is	   marked	   by	   a	   progression	   of	   cognitive	  impairment	   including	   hallucinations	   and	   delusions	   [25].	   Talking	   becomes	   very	   difficult	   and	  simple	  acts	  of	  everyday	  life	  are	  problematic.	  This	  stage	  is	  often	  considered	  the	  most	  difficult	  to	  support	   for	   the	   family	   [6].	  The	   last	   clinical	   stage	  of	   the	  disease	   is	  marked	  by	  a	   loss	  of	   contact	  with	  the	  world	  and	  mutism	  [5].	  The	  patient	  becomes	  totally	  dependent	  on	  the	  caregivers	  and	  is	  affected	   by	   psychomotor	   disorders,	   which	   make	   him	   very	   vulnerable	   to	   infections	   that	   are	  generally	   common	  causes	  of	  death	   [5,	  6].	  The	  progression	  of	   the	  disease	   is	  never	  experienced	  exactly	  the	  same	  way	  from	  one	  person	  to	  another	  and	  some	  symptoms	  may	  occur	  at	  any	  time	  of	  the	  disease.	  However,	  this	  classification	  allows	  families	  and	  caregivers	  to	  assess	  the	  progression	  of	  the	  disease	  and	  plan	  necessary	  measures	  to	  cope	  with	  future	  needs.	  	  	  
	  
FIG.	  1:	  Progression	  of	  symptoms	  of	  Alzheimer’s	  disease	  [25].	  
MMSE:	  Mini	  Mental	  Status	  Examination.	  MCI:	  Mild	  Cognitive	  Impairment.	  AD:	  Alzheimer’s	  disease.	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3.2	  Neuropathology	  
	  From	   a	   neuropathological	   point	   of	   view	   Alzheimer’s	   disease	   is	   a	   chronic	   neurodegenerative	  disorder	  defined	  by	  a	  massive	  and	  progressive	  cell	   loss	   in	   the	  brain	   [26]	  and	  characterized	  by	  the	  deposition	  of	  neuritic	  plaques	  and	  neurofibrillary	  tangles	  in	  many	  regions	  of	  the	  brain	  [27].	  The	  first	  brain	  areas	  to	  be	  affected	  by	  neurodegeneration	  and	  neuronal	  cell	  death	  are	  mainly	  the	  entorhinal	  cortex	  and	  the	  hippocampus,	  which	  are	  key	  areas	  in	  the	  storage	  of	   information	  [28,	  29].	  With	  the	  progression	  of	  the	  disease,	  degeneration	  gradually	  reaches	  other	  cortical	  regions.	  Neuritic	  plaques	  and	  neurofibrillary	  tangles	  represent	  the	  pathological	  hallmarks	  of	  AD,	  and	  are	  respectively	   related	   to	   the	   accumulation	   of	   the	   beta-­‐amyloid	   peptide	   (Aβ)	   and	   to	   cytoskeletal	  changes,	  which	  will	  be	  discussed	  in	  more	  detail	  later	  [26].	  	  	  The	   pre-­‐symptomatic	   phase	   or	   mild	   cognitive	   impairment	   (MCI)	   already	   presents	   some	  structural	  alterations	  in	  limbic	  regions,	  which	  includes	  the	  hippocampus	  [19].	  This	  condition	  is	  thought	   to	   last	   for	   approximately	   7	   to	   10	   years	   until	   the	   overproduction	   and	   accumulation	   of	  abnormal	   structures	   in	   the	   brain	   reach	   a	   critical	   level	   and	   the	   symptoms	   become	   more	  important	   [19].	   The	   morphological	   changes	   observed	   during	   this	   stage	   can	   also	   be	   seen	   in	  normal	   aging.	   It	   is	   therefore	   not	   certain	   that	   all	   people	  with	  MCI	   develop	  Alzheimer’s	   disease	  and	  this	  overlap	  with	  normal	  aging	  makes	  the	  diagnosis	  of	  this	  disease	  more	  difficult	  [30].	  	  The	  initial	  state	  of	  the	  disease	  is	  an	  early-­‐stage	  pathology	  ranging	  from	  mild	  neuronal	  dystrophy	  to	  early-­‐stage	  Braak	  pathology	  [28,	  29,	  31].	  This	  phase	  may	   last	   for	  several	  years	  according	  to	  individual	  brain	  reserve.	  The	  second	  phase	  or	  moderate	  AD	  is	  established	  when	  the	  progression	  of	  neuronal	  damage	  extends	  to	  the	  adjacent	  brain	  regions	  with	  a	  worsening	  of	  clinical	  symptoms	  and	  a	  decline	  of	  cognitive	  functions	  [28,	  29,	  31].	  The	  third	  and	  clinically	  defined	  dementia	  phase	  of	  AD	  is	  characterized	  by	  severe	  cognitive	  and	  functional	  impairment.	  	  	  The	  Braak	  staging	  is	  a	  method	  described	  by	  Braak	  and	  Braak	  in	  1991,	  and	  is	  used	  to	  classify	  the	  degree	   of	   the	   pathology	   in	   Alzheimer’s	   disease	   based	   on	   the	   distribution	   pattern	   of	  neurofibrillary	  changes	  [31].	  It	  is	  most	  often	  used	  in	  research	  and	  is	  determined	  by	  performing	  an	  autopsy	  of	  the	  brain.	  Braak	  and	  Braak	  noticed	  that	  the	  disease	  always	  starts	  at	  the	  same	  place	  and	  that	  the	  neurofibrillary	  degeneration	  develops	  sequentially	  [29,	  31].	  They	  distinguished	  six	  stages	   that	   they	  associated	  with	  different	   cognitive	   functioning.	   Stages	   I	   and	   II	   are	  used	  when	  neurofibrillary	   tangles	  are	  confined	  mainly	   to	   the	   transentorhinal	   region	  of	   the	  brain	  reaching	  the	  second	  layer	  of	  the	  entorhinal	  cortex	  and	  the	  hippocampal	  CA1	  sector	  [31].	  Stages	  III	  and	  IV	  when	  there	  is	  a	  severe	  involvement	  of	  limbic	  regions	  such	  as	  the	  hippocampus.	  The	  number	  of	  neurofibrillary	  tangles	  increases	  in	  the	  affected	  areas	  and	  extends	  without	  the	  amygdala	  and	  the	  temporal	  neocortex	   [31].	  The	   last	   stages,	  V	   and	  VI,	   are	  marked	  by	   cortical	   destruction	   and	  an	  extensive	   neocortical	   involvement	   [31].	   Figure	   2	   shows	   the	   distribution	   pattern	   of	  neurofibrillary	  tangles	  described	  by	  Braak	  and	  Braak.	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FIG.	  2:	  Distribution	  pattern	  of	  neurofibrillary	  tangles.	  	  «	  Six	  stages	  (I-­‐VI)	  can	  be	  distinguished.	  Stages	  I-­‐II	  show	  alterations,	  which	  are	  virtually	  confined,	  to	  
a	   single	   layer	   of	   the	   transentorhinal	   region.	   The	   key	   characteristic	   of	   stages	   III-­‐IV	   is	   the	   severe	  
involvement	  of	   the	  entorhinal	  and	  transentorhinal	  regions.	  Stages	  V-­‐VI	  are	  marked	  by	   isocortical	  
destruction.	  Increasing	  density	  of	  shading	  indicates	  increasing	  severity	  of	  neurofibrillary	  changes.	  »	  [29]	  
	  
	  
3.3	  Etiology	  and	  risk	  factors	  	  The	  exact	  cause	  of	  AD	  is	  still	  not	  known,	  but	  today,	  it	  is	  assumed	  that	  there	  is	  an	  interaction	  of	  several	  factors	  [26,	  27].	  It	  has	  been	  shown	  that	  it	  is	  possible	  to	  preserve	  a	  good	  mental	  shape	  by	  having	  a	  good	  physical	  and	  mental	  condition,	  which	  helps	  decreasing	  the	  risk	  of	  developing	  the	  disease	  [6].	  However,	  a	  number	  of	  risk	  factor	  is	  beyond	  our	  influence,	  one	  of	  the	  most	  important	  one	  is	  age.	  The	  risk	  of	  developing	  a	  cognitive	  impairment,	  still	  low	  at	  the	  age	  of	  60,	  doubles	  every	  five	   years	   thereafter	   [1].	   Indeed,	   while	   AD	   is	   not	   an	   inevitable	   consequence	   of	   aging,	   its	  frequency	   increases	  dramatically	   as	   people	   age	   into	   their	   70's	   and	  beyond.	   It	   is	   also	   assumed	  that	  other	  factors	  –	  not	  yet	  identified	  –	  may	  trigger	  or	  accelerate	  brain	  lesions	  [15].	  	  Genetic	  variations	  play	  an	  important	  role	  in	  the	  autosomic	  form	  of	  the	  disease,	  which	  represents	  2-­‐3%	  of	  all	  AD	  cases	  [32].	  A	  possible	  family	  component	  was	  suggested	  early	  in	  the	  discovery	  of	  this	   condition	   and	   evidences	   for	   a	   genetic	   component	   for	   AD	  were	   developed	   by	   a	   variety	   of	  sources	  [32,	  33,	  34].	  More	  over,	  many	  studies	  have	  found	  an	  important	  frequency	  of	  the	  disease	  in	   relatives	   of	   patients	   suffering	   from	   AD	   [32,	   33].	   It	   was	   then	   highlighted	   that	   a	   familiar	  component	  was	   associated	  with	   a	   very	   early	   onset	   of	   the	   disease	   [31].	   Since	   this	   discovery,	   a	  number	   of	   mutations	   in	   different	   genes	   have	   been	   identified,	   which	   may	   play	   a	   role	   in	   the	  incidence	   of	   familial	   AD.	   One	   of	   these	   genes	   encodes	   for	   the	   precursor	   of	   the	   protein	   beta-­‐amyloid	  (APP),	  while	   the	  other	  ones,	  encode	   for	   transmembrane	  proteins,	  Presenilins	  1	  and	  2,	  which	   are	   implicated	   in	   multiple	   cellular	   processes	   including	   the	   Aβ	   peptide	   pathway	   [34].	  Another	   gene,	   encoding	   for	   the	   apolipoprotein	   E,	   has	   also	   been	   associated	   with	   familial	  Alzheimer’s	   disease	   [34].	   In	   this	   case,	   it	   is	   not	   a	  mutation	  but	   a	   genetic	   polymorphism,	  which	  makes	   these	  people	  more	  prone	   to	   the	  disease	   [31].	  The	  apolipoprotein	  E	  gene	  exists	   in	   three	  different	  forms	  or	  alleles	  (E2,	  E3,	  E4),	  each	  producing	  a	  slightly	  different	  protein.	   It	   is	  only	  the	  presence	  of	  the	  E4	  allele,	  which	  is	  a	  risk	  factor	  for	  the	  disease	  [31].	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Fig. 4. Distribution pattern of neurofibrillary (NF) changes [neu- 
rofibriUary tangles (NFT) and neuropil threads (NT)]. Six stages 
(I-VI) can be distinguished. Stages I-II show alterations which are 
virtually confined to a single layer of the transentorhinal region 
(transentorhinal I-II). The key characteristic of stages III-IV is the 
severe involvement of the entorhinal and transentorhinal layer 
Pre-ct (limbic III-IV). Stages V-VI are marked by isocortical 
destruction (isocortical V-VI). Increasing density of shading 
indicates increasing severity of NF changes 
and in particular its wedge-shaped extremity superim- 
posing the subiculum is affected by modest numbers of 
NFT (see Fig. 8, third row, and Fig. 9, second row). The 
magnocellular forebrain nuclei and the antero-dorsal 
nucleus of the thalamus remain spared or show only mild 
changes. A few isolated NFT may inconstantly be 
encountered in isocortica  associatio  areas. 
Stages I and II are characterized by the transentorhi- 
nal region being preferentially affected with only mild 
involvement of the hippocampus (CA1) and virtual 
absence of isocortical changes (Figs. 4, 9). They are, 
therefor , r ferred to as the "transentorhinal stages". 
Stage IlL The characteristic feature of the third stage is a 
severe involvement of layer Pre-a, both in the transen- 
torhinal and entorhinal region. Many of the projection 
eurons within Pre-(x contain a NFT. Numerous den- 
drites of these cells harbor NT, frequently rendering 
recognition of the extent of the dendritic tree possible. 
For the first time the presence of "ghost tangles" can be 
observed in the transentorhinal layer Pre-c~. A few NFT 
are also encountered in layers Pri-a and Pre-~ (Figs. 6a, 
7, and Fig. 9, third row). 
The hippocampal formation shows an only modest 
involvement of CA1 (Fig. 7, Fig. 8, third row, and Fig. 9, 
third row). Pyramidal cells of the subiculum start to 
develop NFT with particularly far-reaching extensions 
into the apical dendrite (Fig. 8o-q, and fourth row). 
Sectors CA2 to CA4 generally remain devoid of changes 
except of a few large multipolar nerve cells located close 
by or within the plexiform layer of the fascia dentata. 
These cells develop coarse NFTwith far-reac ing exten- 
sion into the dendrites (Fig. 8c, d). 
The isocortex remains virtually devoid of changes or 
is only mildly affected. Some individuals exhibit the 
presence of a few scattered NFTand NT within layers III 
and V in basal portions of frontal, temporal and occipital 
association areas. Others merely reveal a few irregularly 
distributed NP in layer III (Fig. 9, third row, and see Fig. 
12). 
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Although	   genetic	   factors	  may	   explain	   a	   part	   of	   the	   development	   of	   the	   disease,	  most	   patients	  with	  AD	  have	  no	  relatives	  suffering	  from	  this	  condition.	  This	  shows	  that	  other	  risk	  factors	  come	  into	  play.	  Age	  is	  often	  mentioned	  as	  the	  principal	  risk	  factor	  but	  other	  processes	  as	  for	  example	  inflammatory	  and	  oxidative	  events	  may	  play	  an	  important	  role	  in	  the	  course	  of	  the	  disease.	  The	  purpose	  of	  the	  present	  study	  is	  to	  better	  understand	  the	  role	  of	   inflammatory	  processes	  in	  the	  development	  of	  the	  sporadic	  form	  of	  AD.	  	  	  
4.	  Accumulation	  of	  altered	  proteins:	  physiopathology	  of	  Alzheimer’s	  disease	  	  	  Analyses	   of	   brain	   tissue	   of	   patients	   with	   Alzheimer’s	   disease	   have	   shown	   many	   molecular	  lesions,	   but	   the	   characteristic	   anomaly,	  which	  predominates,	   is	   the	   accumulation	  of	  misfolded	  proteins	   resulting	   in	   cerebral	   dysfunction	   [35].	   Two	   major	   components	   present	   significant	  abnormalities	  in	  Alzheimer’s	  disease	  tissue:	  the	  β-­‐amyloid	  peptide	  and	  the	  tau	  protein	  [27].	  	  The	  major	  assumption	  about	  AD	  is	  the	  Aβ	  hypothesis,	  which	  states	  that	  the	  accumulation	  of	  a	  β-­‐amyloid	   peptide	   could	   trigger	   a	   complex	   cascade	   downstream	   that	   could	   result	   in	   cognitive	  deficits	   [30].	   The	   Aβ	   peptide	   is	   generated	   from	   a	   sequential	   proteolysis	   of	   a	   transmembrane	  protein	   precursor,	   the	   amyloid	   precursor	   protein	   (APP),	   which	   is	   ubiquitously	   expressed	   in	  neuronal	   and	   non-­‐neuronal	   cells.	   APP	   can	   be	   processed	   by	   three	   proteases,	   the	  α-­‐,	  β-­‐,	   and	   γ-­‐proteases	  [27].	  According	  to	  the	  pathway	  that	  leads	  to	  the	  hydrolysis	  of	  the	  APP,	  the	  final	  result	  will	   be	   different.	   Studies	   have	   shown	   that	   alterations	   in	   these	   processes	   could	   cause	   the	  accumulation	  of	  an	  abnormal	  Aβ	  product,	  which	  then	  aggregates	  into	  amyloid	  plaques	  and	  may	  play	  a	  central	  role	  in	  the	  pathogenesis	  of	  the	  neurodegeneration	  [26,	  27,	  35].	  	  	  The	  cleavage	  by	  the	  proteases	  can	  follow	  two	  different	  pathways.	  In	  the	  first	  one,	  also	  called	  the	  non–amyloidogenic	  pathway,	  the	  amyloid	  precursor	  protein	  is	  cleaved	  by	  the	  α-­‐secretase.	  In	  this	  case,	  the	  cleavage	  of	  the	  APP	  occurs	  within	  the	  Aβ	  region,	  which	  can	  no	  longer	  be	  produced	  [27,	  36].	  The	  second	  one,	  called	  the	  amyloidogenic	  pathway	  leading	  to	  the	  Aβ	  peptide	  generation,	  is	  mediated	   by	   the	  β-­‐secretase	  which	   leaves	   intact	   the	  Aβ	   region	  within	   the	  membrane.	   Then,	   a	  subsequent	  cleavage	  by	  the	  γ-­‐secretase	  liberates	  the	  Aβ	  peptide	  in	  the	  extracellular	  space,	  which	  aggregate	   into	   insoluble	   oligomers	   [27,	   36].	   This,	   further	   originate	   fibrillary	   Aβ	   species	   that	  accumulate	  into	  senile	  and	  neuritic	  plaques,	  that	  might	  lead	  to	  synaptic	  damages	  and	  ultimately	  to	  neurodegeneration	  [26].	  The	  exact	  mechanism	  by	  which	  such	  damages	  are	  caused	  is	  not	  fully	  understood,	   but	   various	   hypotheses	   explain	   them,	   as	   for	   example	  mitochondrial	   dysfunctions,	  lysosomal	  failure	  and	  alterations	  in	  signalling	  pathways	  [35].	  The	  figure	  below	  illustrates	  these	  processes.	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FIG.	  3:	  Processing	  of	  Amyloid	  Precursor	  Protein.	  	  «	   On	   the	   right	   side,	   cleavage	   by	   α-­‐secretase	   initiates	   non-­‐amyloidogenic	   processing.	   A	   large	  
amyloid	  precursor	  protein	  (sAPPα)	  ectodomain	  is	  released,	  leaving	  behind	  an	  83-­‐residue	  carboxy-­‐
terminal	  fragment.	  C83	  is	  then	  digested	  by	  γ-­‐secretase,	  liberating	  extracellular	  p3	  and	  the	  amyloid	  
intracellular	  domain	  (AICD).	  On	  the	   left	  side,	  amyloidogenic	  processing	   is	   initiated	  by	  β-­‐secretase	  
releasing	  a	  shortened	  sAPPα.	  The	  retained	  C99	  is	  also	  a	  γ-­‐secretase	  substrate,	  generating	  Aβ	  and	  
AICD.	  AICD	  is	  targeted	  to	  the	  nucleus	  signalling	  transcription	  activation.	  Soluble	  Aβ	  is	  then	  prone	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5.	  Inflammatory	  hypothesis	  	  	  In	   Alzheimer's	   disease,	   brain	   regions	   affected	   by	   neuronal	   degeneration	   show	   an	   increase	   in	  astrocytes	   density	   suggesting	   a	   reactive	   astrogliosis	   [39,	   40].	   Reactive	   gliosis	   is	   a	   complex	  response	   that	   occurs	   following	   an	   injury	   or	   a	   damage	   of	   the	   brain	   tissue	   for	   example	   during	  neurodegenerative	  diseases.	  This	  gliosis	   is	   characterized	  by	   the	  proliferation	  and	   transition	   to	  an	  active	  state	  of	  the	  glia,	  i.e.	  astrocytes	  and	  microglia,	  and	  by	  an	  increased	  permeability	  of	  the	  blood-­‐brain	   barrier	   [41].	   Given	   that	   these	   activated	   astrocytes	   are	   localized	   preferentially	  around	   senile	   plaques	   several	   hypotheses	   support	   the	   idea	   that	   other	   factors,	   including	  inflammatory	   processes	   and	   oxidative	   stress,	   may	   play	   a	   key	   role	   in	   the	   pathogenesis	   of	  Alzheimer’s	  disease	  [39,	  42,	  43,	  44].	  	  	  The	   main	   role	   of	   inflammatory	   processes	   in	   the	   central	   nervous	   system	   is	   to	   maintain	  homeostasis	  by	  fighting	  infections	  and	  preventing	  microorganisms	  to	  cause	  too	  much	  damage	  to	  the	  tissues.	  The	  immune	  cells	  present	  in	  the	  brain	  are	  microglia	  and	  astrocytes	  whose	  main	  role	  is	   to	   phagocytose	   and	   degrade	   toxic	   products	   [40,	   45,	   46].	  Microglia	   is	   a	   population	   of	   brain-­‐resident	  cells	  that	  have	  the	  same	  characteristics	  of	  macrophages	  whose	  normal	  function	  in	  the	  brain	   is	   immune	   surveillance.	   They	   are	   the	   first	   cell	   type	   to	   respond	   to	   any	   perturbation	   or	  injury	   within	   the	   central	   nervous	   system	   [40].	   Astrocytes	   on	   the	   other	   hand	   are	   the	   most	  frequent	   cells	   of	   the	   brain.	   They	   have	   multiple	   functions	   that	   allow	   neurons	   to	   mature	   and	  specialize	  for	  the	  tasks	  of	  information	  processing	  but	  it	  has	  been	  shown	  that	  they	  can	  also	  play	  an	  important	  role	  in	  inflammatory	  processes	  [39,	  40].	  These	  two	  types	  of	  immune	  cells	  normally	  remain	   in	   a	   quiescent	   stay	   until	   an	   infection	   or	   an	   injury	   activates	   them	   [47].	   Once	   activated,	  they	  acquire	  the	  ability	  to	  secrete	  a	  variety	  of	  pro-­‐inflammatory	  molecules	  such	  as	  interleukin-­‐1	  (IL-­‐1)	   and	   tumour	   necrosis	   factor	   α	   (TNF-­‐α)	   [47,	   48,	   49,	   50,	   51].	   This	   acute	   inflammatory	  response	   is	   essential	   to	   promote	   the	   migration	   and	   activation	   of	   other	   components	   of	   the	  immune	  system	  to	  the	  compromised	  area	  and	  to	  respond	  immediately	  to	  the	  injury	  [44].	  	  	  A	   chronic	   response	   occurs	   when	   the	   harmful	   stimulus	   persists	   over	   time.	   The	   inflammatory	  process	   transforms	   into	   a	   long-­‐standing	   and	   often	   self-­‐perpetuating	   neuroinflammatory	  response,	  which	   in	   the	  end	  could	  have	  detrimental	  consequences	   for	  neurons	  [40,	  44].	  Fuster-­‐Matanzo	  and	  colleagues	  showed	  that	  chronically	  activated	  microglia	  and	  astrocytes	  could	  induce	  necrosis	   in	   adjacent	   neurons	   by	   releasing	   highly	   toxic	   products	   such	   as	   reactive	   oxygen	  intermediates,	  nitric	  oxide	  and	   inflammatory	   cytokines	   [52].	  Thus,	   chronic	  neuroinflammation	  may	   have	   a	   double	   effect,	   it	   can	   be	   useful	   for	   neuroprotection	   –	   as	   a	   normal	   physiological	  process	  essential	  in	  the	  defence	  against	  microorganisms	  or	  external	  aggression	  and	  to	  promote	  tissue	   repair	   –	   but	   an	   excessive	   inflammatory	   response	   may	   in	   some	   cases	   be	   harmful	   and	  interfere	  with	  normal	  brain	  functions	  [42,	  47].	  This	  chronic	  inflammation	  cycle	  could	  play	  a	  role	  in	   the	   development	   or	   the	   progression	   of	   neurodegenerative	   diseases	   such	   as	   Alzheimer’s	  disease	  [42,	  44,	  53].	  	  	  It	   is	   thought	   that	   in	   this	   pathological	   condition	   the	   inflammatory	  mediators	   such	   as	   cytokines	  and	  chemokines	  could	  alter	  the	  normal	  structure	  of	  the	  brain	  [54].	  We	  know	  for	  example	  that	  a	  variety	  of	  brain	  lesions	  result	  in	  an	  inflammatory	  response,	  which	  exacerbate	  brain	  damage	  by	  increasing	   oxidative	   stress	   [44,	   55].	  More	   over	   studies	   in	   animals	   have	   shown	   that	   prolonged	  brain	   inflammation	   may	   interfere	   with	   the	   normal	   processes	   of	   the	   brain	   such	   as	   impairing	  functions	   of	   the	   hippocampus,	   the	   brain	   region	   involved	   in	   the	   generation	   and	   storage	   of	  memory	   [56].	   Other	   neurodegenerative	   diseases,	   such	   as	   amyotrophic	   lateral	   sclerosis	   or	  Parkinson	  disease,	  also	  show	  signs	  of	  inflammation	  at	  the	  onset	  of	  symptoms	  and	  it	  is	  supposed	  that	  inflammation	  could	  have	  an	  important	  role	  in	  the	  pathogenesis	  of	  these	  disorders	  [57].	  All	  these	  observations	   led	   to	  an	  “inflammatory	  hypothesis”,	  which	  suggests	   that	   the	   inflammatory	  factors	   produced	   by	   the	   activated	   immune	   cells	   of	   the	   brain	   could	   damage	   neurons,	   axonal	  processes	  and	  synapses	  leading	  to	  the	  symptoms	  of	  Alzheimer’s	  disease	  [44,	  48,	  49,	  52].	  Another	  argument	  in	  favour	  of	  this	  hypothesis	  comes	  from	  the	  results	  obtained	  by	  Russo	  and	  colleagues	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showing	  that	  genetic	  polymorphisms	  of	  certain	  inflammatory	  cytokines	  and	  their	  receptors	  can	  modulate	   the	   risk	   of	   neurodegenerative	   diseases	   [48].	   Furthermore,	   they	   have	   shown	   that	  modulation	  of	  these	  inflammatory	  molecules	  in	  animal	  cell	  models	  could	  be	  effective	  in	  the	  fight	  against	  the	  disease	  process	  [48].	  	  	  Chronic	   inflammation	   often	   begins	   insidiously	   as	   a	   smouldering	   and	   asymptomatic	   response.	  Thus,	   it	   may	   happen	   several	   years	   before	   the	   damage	   caused	   by	   inflammation	   is	   important	  enough	  to	  interfere	  with	  the	  proper	  functioning	  of	  the	  brain	  and	  the	  disease	  becomes	  clinically	  detectable.	   Alzheimer’s	   disease	   is	   characterized	   by	   a	   long	   pre-­‐clinic	   period	   during	   which	   the	  brain	  is	  confronted	  to	  increasing	  amounts	  of	  toxic	  Aβ	  peptides	  [19].	  It	  is	  supposed	  that	  amyloid	  deposition	   begins	   10	   to	   20	   years	   before	   the	   appearance	   of	   clinical	   dementia	   [40].	   Increase	   of	  glial	  cells	  and	  expression	  of	  inflammatory	  cytokines	  have	  been	  observed	  in	  AD	  brains	  and	  these	  immune	   cells	   are	   found	   in	   large	   concentrations	   around	   β-­‐amyloid	   plaques	   suggesting	   a	   local	  increased	   activity	   of	   inflammatory	   processes	   in	   these	   specific	   regions	   [52].	   It	   is	   also	   assumed	  that	   the	   activation	   of	   these	   inflammatory	   processes	   may	   activate	   caspases	   leading	   to	   the	  cleavage	   of	   nuclear	   and	   cytoskeletal	   proteins	   including	   tau	   protein	   and	   thus	   promoting	   the	  formation	  of	  neurofibrillary	  tangles	  [38].	  	  	  More	  over	  it	  has	  been	  demonstrated	  that	  an	  inflammatory	  environment	  may	  also	  influence	  the	  temporal	  and	  spatial	  relationship	  in	  the	  neural	  stem	  cell	  niche	  affecting	  the	  neurogenesis,	  i.e.	  the	  formation	  of	  new	  neurons	  [48].	  Damaged	  neurons	  can	  normally	  be	  repaired	  by	  the	  activation	  of	  neuronal	   stem	   cells.	   	   Inflammation	   could	   then	   have	   an	   important	   impact	   on	   the	   efficiency	   of	  brain	  functions	  and	  repair,	  which	  are	  essential	   for	  patients	  with	  Alzheimer’s	  disease	  who	  need	  to	  adapt	  and	  maintain	  their	  brain	  functionality	  despite	  the	  neuronal	  loss.	  Besides,	  neurogenesis	  normally	  contributes	   to	   the	   improvement	  of	   learning	  and	  memory	   that	  are	   the	  main	  cognitive	  deficits	  in	  AD	  [52].	  	  	  The	   results	   of	   these	   studies	   support	   a	   role	   of	   inflammation	   in	   the	   development	   of	  neurodegenerative	  disorders	   such	   as	  Alzheimer's	   disease.	   Furthermore,	   they	   support	   the	   idea	  that	   chronic	   inflammation	   may	   be	   one	   of	   the	   earliest	   events	   in	   the	   disease	   and	   may	   last	   for	  several	   years	   before	   clinical	   symptoms	   appear.	   The	   chronic	   release	   of	   pro-­‐inflammatory	  molecules	  is	  likely	  to	  maintain	  a	  prolonged	  cascade	  of	  proteins	  secretion	  that	  may	  contribute	  to	  the	   neurodegeneration	   [49].	   It	   is	   however	   not	   clear	   whether	   these	   immune	   changes	   are	   a	  consequence	   of	   the	   pathological	   amyloid	   aggregation	   or	   contribute	   to	   its	   pathogenesis.	   Two	  different	  models	  support	  this	  inflammatory	  hypothesis	  [54,	  52].	  The	  main	  hypothesis	  claims	  that	  the	   inflammatory	   cells	   are	   chronically	   activated	   as	   a	   response	   to	   the	   accumulation	   of	   Aβ	  deposition	  [52].	  The	  other	  assumption	  is	  that	  the	  initial	  events	  in	  the	  pathogenesis	  of	  the	  disease	  are	   due	   to	   inflammatory	   events	   occurring	   in	   the	   periphery,	   such	   as	   for	   example	   vascular	  inflammation	  and	  atherosclerosis	  causing	  a	  consequent	  accumulation	  and	  deposition	  of	  amyloid	  proteins	  [57].	  The	  mechanism	  by	  which	  cytokines	  could	  stimulate	  Aβ	  production	  is	  complex	  and	  not	   well	   understood	   but	   a	   study	   suggested	   that	   the	   cleavage	   of	   the	   APP	   protein	   could	   be	  disturbed	  [49].	  Some	  models	  supporting	  this	  hypothesis	  suggest	  the	  existence	  of	  a	  cycle	  in	  which	  inflammatory	  changes	  lead	  to	  the	  accumulation	  of	  Aβ	  protein,	  which	  then	  stimulates	  glial	  cells	  to	  produce	  more	   inflammatory	  mediators	   [50].	   Although	   this	   discussion	   remains	   open,	   it	   shows	  some	   evidence	   on	   the	   role	   of	   inflammatory	   processes	   in	   the	   development	   and/or	   the	  progression	  of	  the	  disease.	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FIG.	  4:	  Potential	  interactions	  of	  Aβ 	  peptide,	  vascular	  inflammation	  and	  cerebral	  
inflammation	  in	  precipitating	  Alzheimer’s	  disease	  pathogenesis.	  «	   This	   scheme	   shows	   that	   peripheral	   disturbances	   (e.g.	   high	   levels	   of	   cholesterol,	   vascular	  
inflammation,	   atherosclerosis)	   may	   cause	   brain	   dysfunction	   by	   initiating	   an	   inflammatory	  
pathway.	  This	  will	  reduce	  transport	  of	  oxygen	  and	  glucose,	  creating	  conditions	  of	  oxidative	  stress	  
that	   can	   increase	  Aβ	   production	  and	  aggregation,	   and	  neuronal	   stress	  directly.	  Deposition	  of	  Aβ	  
can	   also	   lead	   to	   cerebral	   inflammation,	   which	   can	   feedback	   to	   increase	   production	   of	   Aβ.	   The	  
contribution	  of	  cerebral	  inflammation	  in	  the	  progression	  of	  pathological	  changes	  remains	  unclear,	  
but	  it	  is	  thought	  that	  inflammatory	  factors	  can	  mediate	  many	  of	  the	  neurotoxic	  events	  occurring	  in	  
AD.	  »	  [57]	  	  	  Supporting	   this	   inflammatory	   hypothesis,	   some	   studies	   have	   suggested	   that	   the	   use	   of	   non-­‐steroidal	   anti-­‐inflammatory	   drugs	   (NSAIDs)	   may	   help	   to	   prevent	   Alzheimer’s	   disease	   by	  modulating	  the	  factors	  involved	  in	  neuroinflammation	  [54,	  57,	  58].	  It	  has	  been	  demonstrated	  by	  these	  studies	  that	  a	  neuroprotective	  effect	  against	  the	  development	  of	  AD	  could	  be	  obtained	  by	  a	  long-­‐term	   use	   of	   NSAIDs	   [54,	   58].	   The	   use	   of	   these	   drugs	   in	   patients	   with	   established	  Alzheimer’s	  disease	  has	  shown	  some	  beneficial	  effects	  on	  cognition	  not	  only	  by	  suppressing	  the	  inflammatory	  effects	  but	  also	  by	  decreasing	  the	  production	  of	  toxic	  Aβ	  peptides	  [58].	  In	  addition,	  it	  has	  been	  demonstrated	  that	  patients	  with	  inflammatory	  diseases	  such	  as	  rheumatoid	  arthritis	  or	  osteoarthritis	  have	  less	  risk	  of	  developing	  AD.	  This	  reinforces	  the	  idea	  of	  a	  possible	  protective	  effect	  of	  anti-­‐inflammatory	  drugs	  [57].	  	  However,	  these	  therapeutic	  studies	  have,	  for	  the	  moment,	  shown	  positive	  results	  only	  in	  a	  small	  proportion	  of	  patients	  and	  other	  randomized	  studies	  present	  inconsistent	  results.	  Indeed,	  recent	  clinical	   trials	   with	   NSAIDs	   based	   on	   the	   hypothesis	   that	   these	   drugs	   could	   prevent	   the	  neurodegenerative	   disorders	   of	   the	   central	   nervous	   system	   show	   no	   significant	   difference	   in	  cognitive	   decline	   between	   NSAIDs	   use	   and	   placebo	   [59,	   60,	   61,	   62,	   63].	   It	   was	   even	  demonstrated	   that	   the	  use	  of	  NSAIDs	   could	  have	  an	  adverse	  effect	   in	  advanced	  disease	   stages	  [64].	  Thus,	  although	   the	   inflammatory	  component	  of	  Alzheimer's	  disease	  has	  been	  established	  by	  various	  studies,	   its	  exact	  role	  in	  the	  disease	  has	  not	  yet	  been	  clearly	  elucidated,	  and	  clinical	  trials	  of	  NSAIDs	  have	  not	  yielded	   the	  expected	   results.	   It	   is	   then	  not	  possible	   to	   conclude	   that	  anti-­‐inflammatory	  treatments	  alone	  are	  a	  valid	  approach	  for	  AD.	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AD, as its incidence is around 1% in the 60-64 year age-group, but 
rising to about 30% in those aged 85 years or older. Associated risk 
factors are head trauma, small brain size, female gender, low educa-
tional status and reduced physical and mental ability in later life 
[20,57,98]. The major genetic risk factor is possession of the apol-
ipoprotein E (apoE) 4 allele [110]. Other risk factors of AD, all of 
which are associated with vascular disease, and some that can be 
affected by possession of the apoE 4, include diabetes, hypercho-
lesterolemia, hypertension, coronary heart disease, obesity, smok-
ing and atherosclerosis [36]. A strong association between cerebral 
atherosclerosis and the development of AD pathology has recently 
been demonstrated [13,23,148]. To date, the only consistent data 
from case-control, cross-sectional epidemiological, and prospective 
incidence studies of subjects concerning what reduces the risk of 
AD were a history of taking NSAIDS (examples [17,18,22,80, 
97,117]). Although some of these earlier studies have limitations 
due to possible selection biases [97], the Baltimore Longitudinal 
Study of Aging, a prospective incidence study, did confirm a re-
duced risk of AD in subjects taking NSAIDS [163]. Similarly, the 
Rotterdam Study of Aging prospective study has demonstrated a 
relative risk of 0.2 (with range 0.05-0.83 at 95% confidence inter-
val) for developing AD in those taking NSAIDS for more than 24 
months [81]. 
 There is no doubt that the pathogenesis of AD is multifactorial 
involving a combination of genetic factors and non-genetic compo-
nents, which together can lead to the generation of toxic processes 
involving dysregulation of amyloid precursor protein metabolism, 
inflammation, oxidative stress, apoptosis, proteosome inhibition, 
mitochondrial dysfunction, imbalances in antioxidant production, 
and glutamate excitotoxicity, amongst others [133]. As such, it 
appears important that new therapeutic agents have multiple targets 
of action that affect a number of these processes. 
Inflammation and AD 
 A comprehensive summary of inflammation and AD was com-
piled about 7 years ago, with the conclusion that inflammation must 
be contributing to AD pathology on account of the many toxic in-
flammatory proteins that are upregulated in AD brains [123]. With 
the apparent lack of effect in clinical trials of tested agents (primar-
ily COX inhibitors) on slowing the progression of mental deteriora-
tion, we should consider whether inflammation is still a relevant 
target for AD. A scheme for how inflammation and A could inter-
act to cause AD pathology is presented in Fig (1). This model 
makes the assumption that the initiating events for neuropathology 
in the brain start in the periphery (i.e. vascular inflammation, athe-
rosclerosis, coronary heart disease) and lead to the initial A depo-
sition; this progression of events is not universally accepted [201]. 
A deposition due to reduced clearance can initiate a cascade of 
events leading to accelerated A oligomerization and aggregation 
that can directly cause synaptic loss and neurodegeneration, and 
ultimately dementia. A is considered by most as the primary driv-
ing force of AD, due to its neurotoxic, oxidative stress and proin-
flammatory effects on multiple cell types. There is evidence that 
cerebral inflammation can lead to increased A production [77]; the 
question that remains to be answered is to what extent inflamma-
tory factors produced in brain directly lead to synaptic damage and 
neurodegeneration; answering this question is central to deciding 
which anti-inflammatory agents should be tested. 
 To be effective, the appropriate anti-inflammatory agent must 
be administered to the appropriate clinical population, who are not 
too far advanced in the disease. If one considers at what stage of the 
disease to administer anti-inflammatory therapeutics, Fig. (2) is 
derived from data from two publications on the relative staging of 
microglia, plaques and NFT in hippocampus and entorhinal cortical 
sections of subjects with progressively increasing clinical dementia 
rating (CDR) scores [170,187]. There is a progressive increase in 
each of these parameters as dementia increases, though both studies 
show a decline in microglia scores as the neuritic plaque progresses 
from stage 3 to 5, or NFT progresses from 5 to terminal stage 6. 
This would indicate that microglia activation could “burn out” at 
the last stages of pathology once mental decline can not be further 
measured. It would appear that at early and moderate stages of AD, 
there is the potential to reduce inflammation, and plaque and tangle 
formation, using drugs that target all features of this pathology. 
Clinical Trials of Anti-Inflammatory Agents with AD Subjects 
 Prospective double-blind placebo-controlled trials are consid-
ered the standard for determining whether an agent is effective for a 
particular disease. A number of trials of anti-inflammatory agents 
have been carried out with AD subjects. The design, dosage, degree 
of severity and inclusion criteria of the patient population was not 
consistent between the trials. The first such trial for AD of a 
NSAID involved a small group of patients treated for 6 months with 
indomethacin or placebo [146]. The indomethacin-treated patients 
Fig. (1). Potential interactions of A peptide, vascular inflammation and cerebral inflammation in precipitating AD pathogenesis. In this scheme, peripheral 
disturbances (e.g. high levels of cholesterol, vascular inflammation, atherosclerosis) lead to compromise/inflammation of the cerebrovasculature. This will 
reduce transport of oxygen and glucose, creating conditions of oxidative stress that can increase A production and aggregation, and neuronal stress directly. 
Deposition of A can lead to cerebral inflammation, which can feedback to increase production of A. The contribution of cerebral inflammation separate 
from A to the progression of pathological changes is unclear, but inflammatory factors can mediate many of the neurotoxic events occurring in AD (tau hy-
perphosphorylation, synaptic loss, neuronal cell death).
	  14	  	  
6.	  Aims	  of	  the	  project	  	  	  This	  project	  tries	  to	  better	  understand	  the	  differences	  between	  the	  normal	  aging	  of	  the	  human	  brain	  and	  the	  processes	   leading	  to	  Alzheimer’s	  disease.	  As	  described	  earlier,	  many	  hypotheses	  exist	  to	  explain	  the	  pathogenesis	  of	  this	  disease,	  however,	  the	  relevance	  of	  theses	  hypotheses	  is	  constantly	  being	  discussed	  and	  questioned	  and	  the	  disease	  remains	  unfortunately	  unexplained	  and	  without	  effective	  treatments	  [30].	  Diagnosis	  and	  therapeutic	  strategies	  might	  greatly	  benefit	  of	  a	  new	  approach	  based	  on	  the	  molecular	  pathogenesis	  of	  the	  disorder	  [15].	  Thus	  the	  detection	  of	   very	   early	   and	   possibly	   preclinical	   stages	   of	   the	   disease	   by	   highlighting	   specific	  molecules	  becomes	  necessary	  for	  the	  efficacy	  of	  future	  targeted	  therapeutic	  strategies.	  	  For	  the	  present	  study,	  attention	  was	  focused	  on	  the	  inflammatory	  hypothesis	  based	  on	  the	  idea	  that	   the	   accumulation	   of	   microglia	   and	   astrocytes	   around	   amyloid	   plaques	   activate	   a	   local	  cytokine-­‐mediated	   response,	   which	   may	   damage	   neurons	   and	   exacerbate	   the	   pathological	  processes	   underlying	   the	   disease	   [39,	   50,	   65].	   The	   release	   of	   cytokines	   and	   chemokines	   will	  cause	  the	  subsequent	  activation	  of	  other	  components	  of	  the	  immune	  response,	  which	  have	  the	  potential	   to	   further	  damage	  neurons	  and	  amplify	   any	  ongoing	   inflammatory	   response	   [40,	  42,	  44].	  It	  is	  assumed	  that	  a	  chronic	  inflammation	  in	  specific	  areas	  of	  the	  brain	  could	  contribute	  to	  the	  worsening	  of	  the	  symptoms	  of	  AD.	  	  	  This	  project	  consists	  on	  the	  analysis	  of	  different	  inflammatory	  molecules	  as	  well	  as	  the	  detection	  of	  characteristic	  proteins	  of	  AD	  in	  brain	  tissues	  from	  the	  entorhinal	  and	  the	  frontal	  region	  from	  control,	  moderate	  and	  severe	  Alzheimer’s	  disease	  patients.	  These	  two	  brain	  regions	  were	  chosen	  for	  their	  importance	  in	  the	  development	  of	  the	  disease	  based	  on	  the	  model	  of	  Braak	  and	  Braak	  which	   states	   that	   the	  disease	   starts	   in	   a	   region	  of	   the	   entorhinal	   cortex	   then	   spreading	   to	   the	  Frontal	  cortex	  and	  other	  cerebral	  areas	  [28,	  29].	  	  The	  three	  molecules	  selected	  to	  target	  the	  inflammatory	  processes	  are	  TNF-­‐α,	  IL-­‐1β	  and	  NF-­‐κB	  and	  were	  chosen	  for	  their	  important	  role	  in	  inflammation	  based	  on	  scientific	  literature	  [45,	  48,	  49,	  52,	  66,	  67,	  68].	  It	  has	  indeed	  been	  demonstrated	  in	  these	  studies	  that	  activated	  microglia	  and	  astrocytes	  in	  AD	  brains	  might	  contribute	  to	  cell	  death	  by	  releasing	  pro-­‐inflammatory	  cytokines	  such	  as	  TNF-­‐α,	  IL-­‐1β	  and	  INF-­‐γ.	  More	  over	  it	  is	  assumed	  that	  these	  pro-­‐inflammatory	  cytokines	  activate	   some	   protein	   kinases	   involved	   in	   tau	   hyperphosphorylation	   [48].	   Another	   study	  suggested	   that	   the	   continuous	   presence	   of	   immune	   activators	   such	   as	   Aβ	  might	   stimulate	   the	  chronic	  state	  of	  inflammation	  in	  AD	  brains	  and	  showed	  that	  cytokines	  such	  as	  TNF-­‐α,	  IL-­‐1β	  and	  IL-­‐6	  can	  be	  directly	  cytotoxic,	  when	  chronically	  produced	  at	  high	  concentrations	  [49].	  It	  was	  also	  suggested	  that	  these	  pro-­‐inflammatory	  cytokines	  might	  in	  combination	  stimulate	  the	  production	  of	  Aβ	  peptide	  [49].	  The	  transcription	  factor	  family,	  NF-­‐κB,	  has	  been	  identified	  as	  playing	  a	  major	  role	   in	   the	   initiation	   of	   the	   innate	   and	   adaptative	   immune	   responses	   by	   regulating	   the	  expression	   of	   several	   genes	   involved	   in	   inflammatory	   and	   immune	   responses.	   Many	   studies	  suggest	   that	   this	  molecule	   should	   be	   considered	   as	   an	   important	  mechanism	   in	   inflammatory	  processes	  and	  autoimmune	  diseases	  [66,	  67,	  68].	  More	  over	  some	  anti-­‐inflammatory	  drugs	  and	  immunosuppressive	   treatments	   inhibit	   NF-­‐κB	   [67].	   Ascolani	   and	   colleagues	   investigated	   the	  expression	  of	  a	  number	  of	  genes	  involved	  in	  the	  inflammatory	  and	  oxidative	  response	  of	  a	  well-­‐defined	   small	   cohort	   of	   sporadic	   AD	   patients	   [69].	   They	   discovered	   that	   the	   expression	   of	  various	   NF-­‐κB	   target	   genes	  were	   increased	   in	   peripheral	   blood	  mononuclear	   cells	   suggesting	  that	  NF-­‐κB	  activation	  could	  be	  a	  potential	  new	  hallmark	  of	  AD	  progression	  [69].	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The	  analyses	  and	  investigations	  of	  this	  research	  focus	  on	  three	  main	  issues:	  	  	  	   1. The	  first	  question	  is	  to	  know	  whether	  significant	  inflammation	  is	  found	  in	  AD	  brains	  and	  if	  so	  at	  what	  stage	  of	  the	  disease	  the	  inflammation	  does	  play	  a	  role?	  	  	   2. The	  second	  issue	  is	  to	  examine	  the	  cerebral	  distribution	  of	  the	  inflammation	  between	  the	  Entorhinal	   and	   the	   Frontal	   cortex	   and	   to	   determine	   if	   there	   is	   a	   significant	   difference	  between	   these	   two	   areas.	   The	   severity	   of	   the	   disease	   varies	   between	   these	   two	   brain	  regions	  and	  thus	  allows	  determining	  whether	  the	  inflammation	  is	  related	  to	  AD	  either	  as	  a	  primary	  and	  early	  event	  or	  as	  a	  secondary	  and	  late	  stage	  process.	  	  3. The	   third	   question	   investigates	   whether	   there	   is	   a	   significant	   correlation	   between	  inflammation	  and	  the	  age	  of	  subjects.	  	  	  The	   results	  of	   this	   study	   could	  help	   to	  better	   apprehend	   the	   role	  of	  neuroinflammation	   in	   the	  development	   of	   Alzheimer’s	   disease	   and	   its	   symptomatology	   and	   to	   assess	   whether	   the	  development	   of	   new-­‐targeted	   therapies	   against	   inflammatory	   processes	   could	   slow	   down	   the	  progression	  of	  the	  disease.	  	  
	  
7.	  Materials	  and	  Methods	  	  	  
7.1	  Tissues	  	  A	  total	  of	  20	  brains	  were	  studied,	  eight	  normal	  control	  cases	  and	  twelve	  sporadic	  confirmed	  AD	  cases	  without	  knowing	   familial	  history,	  all	  going	   from	  59	   to	  87	  years	  of	  age.	  Clinical	  diagnosis	  was	   confirmed	  by	  neuropathological	   post-­‐mortem	  examination.	   In	   addition,	  Alzheimer’s	   cases	  were	   separated	   into	   two	   groups	   depending	   on	   the	   severity	   of	   the	   disease:	   six	   cases	   with	  moderate	  AD	  (Braak	  stages	  II-­‐III-­‐IV	  on	  post-­‐mortem	  examination)	  and	  six	  cases	  with	  severe	  AD	  (Braak	  stages	  V-­‐VI	  on	  post-­‐mortem	  examination).	  The	  cause	  of	  death	  and	  the	  post-­‐mortem	  delay	  (PMD)	  are	  also	  indicated.	  	  
	  
 
Case Sex Age PMD  
(hours) 
Group Cause of death 
1 F 88 13 Control Myocardial Infarction 
2 F 79 12 Control Bronchopneumonia  
3 F 81 12 Control Pulmonary cancer 
4 M 72 7 Control Heart failure 
5 F 59 18 Control Septic choc 
6 M 85 14 Control Prostatic cancer 
7 M 73 7 Control Heart failure 
8 F 75 6 Control Unknown 
9 F 95 9 AD moderate Septic choc + BP 
10 F 80 6.5 Braak II Pulmonary Embolism 
11 F 92 12 AD moderate Bronchopneumonia 
12 F 88 7 Braak III Bronchopneumonia 
13 F 87 22 Braak II Bronchopneumonia+ AOP 
14 F 90 22 Braak IV High digestive haemorrhage 
15 M 84 2.5 AD severe AD + Vascular dementia 
16 F 78 6 Braak VI AD + Diabetes + HTA 
17 M 72 9 Braak V Unknown 
18 F 78 4 AD severe AD + Diabetes + HTA 
19 F 83 23 Braak VI Unknown 
20 F 87 12 AD severe Unknown 
BP: Bronchopneumonia; AOP : acute pulmonary oedema; HTA: Hypertension 
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7.2	  Antibodies	  	  	  
Firts	  Antibodies	  
	  
Used	  to	  detect	  a	  specific	  protein	  on	  the	  autopsy	  tissue	  Anti-­‐GFAP	  	   Rabbit	   polyclonal	   antibody	   Anti-­‐Glial	   Fibrillary	   Acidic	   Protein	   –	   GFAP	  (1:2’000	  dilution)	   from	  Sigma	  (G-­‐9269).	  GFAP	   is	  a	  major	   intermediate	  filament	  protein	  and	  a	  major	  cytoskeletal	  structure	  of	  astrocytes.	  	  Anti-­‐AD2	  	   Mouse	   monoclonal	   antibody	   AD2	   (1:10’000	   dilution)	   from	   BioRad	  (56484)	   reacts	   with	   the	   Tau	   protein	   and	   more	   specifically	   with	   the	  upstream	   flanking	   region	   of	   the	   microtubule-­‐binding	   domain	   when	  Ser396	   and	   Ser404	   are	   phosphorylated.	   These	   are	   phosphorylation	  sites,	   which	   remain	   stable	   in	   neurofibrillary	   lesions	   even	   in	   autopsy	  tissues	  thus	  making	  AD2	  useful	   for	  the	  detection	  of	   the	  neurofibrillary	  tangles	  in	  AD	  brains.	  	  	  Anti-­‐β-­‐amyloid	  	   Mouse	  monoclonal	  antibody	  β-­‐amyloid	  peptide	  1-­‐42	  (1	  :1'000	  dilution)	  from	  DAKO.	  β-­‐amyloid	   is	   the	  major	   component	   of	   amyloid	   plaques	   in	  association	  with	  Alzheimer’s	  disease.	  	   	  Anti-­‐TNF-­‐α	  	   Mouse	   monoclonal	   antibody	   TNF-­‐α	   (1:2’000	   dilution)	   from	   Abcam	  (ab1793).	   Tumor	   necrosis	   factor-­‐alpha	   is	   a	   pleiotropic	   inflammatory	  cytokine,	  which	  serves	  a	  variety	  of	  functions	  during	  inflammation	  as	  for	  example	  neutrophil	  proliferation.	  	  Anti-­‐NF-­‐KB	  	   Mouse	  monoclonal	  antibody	  NF-­‐kB	  (1:100	  dilution)	   from	  LabForce	  AG	  (SC-­‐8414).	   Nuclear	   factor	   kappa-­‐light-­‐chain-­‐enhancer	   is	   a	   protein	  complex	   responsible	   for	   cytokines	   production	   in	   response	   to	   stimuli	  such	  as	  stress,	  free	  radicals,	  irradiation	  and	  inflammatory	  processes.	  	  Anti-­‐IL-­‐1β	  	   Mouse	  monoclonal	   antibody	   IL-­‐1β	   (1:100	   dilution)	   from	   LabForce	   AG	  (SC-­‐32294).	   Interleukin-­‐1	   beta	   also	   known	   as	   catabolin	   is	   a	   cytokine	  protein,	  which	  is	  an	  important	  mediator	  of	  the	  inflammatory	  response,	  and	   is	   involved	   in	   a	   variety	   of	   cellular	   activities,	   including	   cell	  proliferation,	  differentiation,	  and	  apoptosis.	  	  
Second	  Antibodies	  
	  
Used	  to	  detect	  the	  first	  antibodies	  ECLTM	  Rabbit	  IgG	  	   HRP-­‐Linked	  (1:2’000	  dilution)	  from	  GE	  Healthcare	  (NA-­‐934).	  ECLTM	  Mouse	  IgG	  	   HRP-­‐Linked	  (1:2’000	  dilution)	  from	  GE	  Healthcare	  (NA-­‐931).	  	  	  
7.3	  SDS-­‐PAGE	  	  	  SDS	   (Sodium	  Dodecyl	  Sulfate)	   is	   the	  most	   common	  dissociating	  agent	  used	   to	  denature	  native	  proteins	   to	   individual	   polypeptides.	   The	   purpose	   of	   this	   method	   is	   to	   separate	   proteins	  according	   to	   their	  size	  and	  no	  other	  physical	   feature.	  SDS	   is	  a	  negative	  charged	  detergent	   that	  can	  dissolve	  hydrophobic	  molecules.	  When	  molecules	  are	   incubated	  with	  SDS,	   the	  membranes	  are	  dissolved	  so	  all	  the	  proteins	  contain	  only	  primary	  structure	  and	  all	  of	  them	  are	  covered	  with	  many	   negative	   charges.	   This	   allows	   the	   proteins,	   when	   placed	   in	   an	   electric	   field,	   to	  migrate	  towards	   the	   anode.	   If	  we	  want	   the	   proteins	   to	   separate	   by	   size,	  we	   need	   to	   put	   them	   into	   an	  environment	   that	   allows	   different	   sized	   proteins	   to	  move	   at	   different	   rates.	   The	   environment	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chosen	   to	   separate	   the	   proteins	   by	   size	   is	   polyacrylamide,	   which	   is	   a	   polymer	   of	   acrylamide	  monomers,	  which	  turns	  into	  a	  gel	  made	  of	  a	  labyrinth	  of	  different	  sized	  pores.	  We	  can	  then	  use	  electricity	  to	  pull	  the	  proteins	  through	  the	  gel.	  This	  entire	  process	  is	  called	  PolyAcrylamide	  Gel	  Electrophoresis	  (PAGE).	  	  Gels	  were	  prepared	  with	  acrylamide	  solution	  (39%	  acrylamide	  stock	  solution	  (Merk),	  1%	  N.N-­‐methylendiacrylamide	   (Merk),	   stacking	   buffer	   (3%	   Tris	   (Sigma),	   0.2%	   SDS	   (BioRad),	   pH:	   6.8,	  separating	  buffer	  (9.1%	  Tris	  (Sigma),	  0.2%	  SDS	  (BioRad),	  pH:	  8.8),	  ammonium	  persulfate	  (APS	  solution	   of	   10%	   (Sigma))	   and	   tetra-­‐methyl-­‐ethylene-­‐diamine	   (TEMED)	   (Eurobio).	   	   Defined	  amounts	   of	   brain	   sample	   were	   then	   separated	   by	   a	   3.6%	   -­‐	   15%	   gradient	   SDS-­‐PAGE.	   The	  acrylamide	   gradient	   gel	   of	   3.6%	   -­‐	   15%	  allows	   separating	  different	  proteins	   according	   to	   their	  molecular	  weight	  in	  the	  molecular	  range	  of	  300	  KD	  to	  15	  KD.	  	  The	  electrophoresis	  was	  done	  with	  140V	  for	  around	  3h	  in	  a	  running	  buffer	  (0.3%	  Tris	  (Sigma),	  1.44%	  Glycine	  (Biosolve),	  0.1%	  SDS	  (BioRad),	   and	   deionised	   water).	   After	   the	   electrophoresis,	   the	   gels	   were	   either	   stained	   by	  Coomassie	  blue	  or	  transferred	  to	  nitrocellulose	  membrane	  for	  Western	  Blotting	  [70].	  	  	  	  
7.4	  Coomassie	  blue	  staining	  	  After	  the	  electrophoresis,	  the	  gels	  were	  incubated	  in	  the	  Coomassie	  brilliant	  blue	  dye	  over	  night.	  This	  allows	  visualizing	  the	  general	  protein	  composition	  of	  the	  brain	  regions	  that	  are	  studied	  and	  to	   correct	   for	   uneven	   protein	   loading.	   The	   same	   samples	   were	   prepared	   for	   Coomassie	   blue	  staining	  and	   for	  Western	  blots	  on	  brain	   tissue	   from	   the	  entorhinal	   and	   frontal	   cortex.	  The	  gel	  usually	  contains	  a	  marker	  of	  known	  molecular	  weight,	  which	  allows	  determining	  the	  molecular	  weight	  of	  the	  proteins	  in	  the	  solution.	  	  	  
7.5	  Western	  Blot	  and	  Chemiluminescence	  	  	  Western	  blot	   is	  an	  analytical	   technique	  used	  to	  detect	  specific	  proteins	   in	   the	  given	  sample.	   In	  order	  to	  make	  the	  proteins	  accessible	  to	  antibody	  detection	  they	  are	  moved	  from	  within	  the	  gel	  onto	   a	   membrane	   made	   of	   nitrocellulose.	   The	   method	   for	   transferring	   the	   proteins	   is	   called	  electroblotting	  and	  uses	  an	  electric	  current	  to	  pull	  proteins	  from	  the	  gel	   into	  the	  nitrocellulose	  membrane.	  It	  consists	  on	  placing	  a	  nitrocellulose	  membrane	  (Reinforced	  NC,	  OptitRan	  BA-­‐S	  85)	  on	  top	  of	   the	  gel,	  and	  a	  stack	  of	   filter	  papers	  (GB003,	  Schleicher	  &	  Schuell)	  on	  top	  of	   that.	  The	  entire	   stack	   is	   placed	   in	   a	   buffer	   solution	   (24.9mM	  Tris	   (Sigma),	   191.8mM	  Glycine	   (Biosolve),	  20%	   methanol	   (Brenntag),	   0.01%	   SDS	   (BioRad)	   and	   deionised	   water)	   by	   orientating	   the	  nitrocellulose	  membrane	   towards	   the	   anode.	   The	   transfer	  was	   done	  with	   25V	   overnight.	   The	  proteins	  moved	  from	  within	  the	  gel	  onto	  the	  membrane	  while	  maintaining	  the	  organization	  they	  had	  within	  the	  gel.	  As	  a	  result,	  the	  proteins	  are	  exposed	  on	  a	  thin	  surface	  layer,	  which	  facilitate	  their	   detection.	   The	   nitrocellulose	   membrane	   is	   chosen	   for	   its	   non-­‐specific	   protein	   binding	  properties	   (i.e.	   binds	   all	   proteins	   equally	   well).	   After	   the	   proteins	   were	   transferred	   to	   a	  nitrocellulose	  membrane,	  they	  were	  stained	  with	  monoclonal	  and	  polyclonal	  antibodies	  specific	  to	   the	   target	   protein.	   Detection	   is	   typically	   performed	   using	   peroxidase-­‐linked	   antibodies	   to	  catalyse	  a	  chemiluminescent	  reaction.	  	  The	   first	   step	   of	   chemiluminescence	   is	   the	   saturation	   of	   the	  membrane,	  which	   helps	   to	   avoid	  non-­‐specific	   binding	   of	   the	   antibodies.	   To	   do	   so,	   the	  membrane	  was	   blocked	   for	   30min	   to	   1h	  with	  5%	  milk	  in	  PBS-­‐Tween20.	  Thus,	  when	  the	  primary	  antibody	  is	  later	  added,	  there	  is	  no	  room	  on	   the	  membrane	   for	   it	   to	  attach	  other	   than	   the	   specific	  binding	   site	   -­‐	   the	  epitope	  of	   targeted	  proteins.	  After	  being	  washed	  for	  15min	  with	  PBS	  (1.34g	  Na2HPO4,	  9.06g	  NaCl	  (Merk),	  pH:	  7.4),	  the	  membrane	  was	  incubated	  during	  1h	  with	  a	  solution	  containing	  the	  first	  antibody	  (ABI,	  PBS,	  2.5%	  milk,	   0.15%	   Tween20),	   which	   will	   detect	   the	   protein	   we	   are	   looking	   for.	   After	   several	  washings	   in	  PBS,	  we	   incubated	   the	  membrane	  during	  1h	  with	   the	  second	  antibody	   linked	   to	  a	  peroxidase	   enzyme	   that	   allows	   detection.	   Finally,	   after	   several	   washings,	   the	   membrane	   was	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incubated	   for	  exactly	  1min	   in	   the	  presence	  of	   the	  detection	  solution	  (Amersham,	  ECL	  Western	  Blotting	  Detection	  Reagents,	  GE	  Healthcare).	  This	   solution	   contains	   a	   substrate	   that	   triggers	   a	  chemiluminiscent	   reaction	   in	   contact	   with	   the	   peroxidase-­‐conjugated	   antibody.	   For	   the	  chemiluminescence	  detection,	   the	  membrane	  was	   then	  exposed	   to	   light	  sensitive	   films	   (Kodak	  Biomax	  MR)	   for	  several	  seconds,	  minutes	  and	  sometimes	  hours,	  and	  the	   films	  were	  developed	  with	  the	  KODAK	  X-­‐OMAT	  1000	  Processor.	  For	  further	  analysis,	  the	  films	  were	  scanned	  with	  an	  Image	  Scanner	  PowerLock	  1120	  UDS	  (GE	  Healthcare).	  	  
	  
FIG.	  5:	  Chemiluminescence	  method	  for	  western	  blot	  detection.	  	  «	  In	  this	  detection	  method,	  a	  primary	  antibody	  is	  added	  first,	  either	  a	  monoclonal	  or	  a	  polyclonal	  
antibody,	  to	  bind	  to	  the	  antigen.	  Then	  a	  labelled	  secondary	  antibody	  is	  used	  directed	  against	  the	  
primary	  antibody	  and	  reacts	  with	  the	  substrate.	  »	  [71]	  	  	  
7.6	  Quantification	  by	  Densitometry	  and	  Statistical	  analyses	  	  	  After	   scanning	   the	   films,	   the	   immunoblots	   were	   analysed	   by	   using	   the	   quantification	   BioLab	  software	   (1-­‐D	  Main,	   American	   Applied	   Biotechnology)	   to	   evaluate	   the	   intensity	   of	   the	   bands.	  Before	   performing	   the	   statistical	   analyses,	   the	   data	   were	   all	   normalized	   and	   adjusted	   to	   the	  levels	  of	  β-­‐actin.	  The	  results	  were	  then	  entered	  into	  an	  Excel	  database	  from	  which	  graphs	  were	  designed.	   Statistical	   analyses	   were	   done	   by	   using	   the	   R	   project	   for	   statistical	   computing	   to	  compare	   the	  differences	   in	   the	  molecular	  density	   among	   the	  groups.	  Three	   comparisons	  were	  made.	  The	   first	  one	  was	  between	   the	  control	  cases	  and	   the	  moderate	  AD	  patients.	  The	  second	  between	   control	   and	   severe	   AD	   cases	   and	   finally	   a	   comparison	   was	   made	   between	   the	   two	  groups	  of	  Alzheimer’s	  disease.	  The	  One	  Way	  Anova	  test	  and	  the	  Tukey’s	  HSD	  test	  were	  used	  to	  determine	  if	  the	  sets	  of	  data	  were	  significantly	  different	  from	  each	  other.	  Statistical	  significance	  was	  considered	  for	  a	  p-­‐value	  <	  0.05.	  A	  result	  is	  statistically	  significant	  when	  it	  is	  unlikely	  that	  it	  could	  be	  obtained	  by	  a	  simple	  chance.	  Usually	   the	  threshold	  of	  0.05	   is	  used,	  which	  means	  that	  the	  observed	  result	  has	  less	  than	  5%	  chances	  to	  be	  obtained	  randomly.	  It	  is	  therefore	  considered	  statistically	  significant.	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8.	  Coomassie	  blue	  gels	  and	  Western	  blots	  
	  The	  Coomassie	  blue	  gels	  show	  equal	  loading	  of	  the	  proteins	  on	  the	  entorhinal	  (Fig	  6.B)	  and	  the	  frontal	   samples	   (Fig	   7.B).	   Some	   proteins	   seem	  more	   abundant	   in	   some	   areas	   as	   for	   example	  sample	  9	  of	  the	  entorhinal	  cortex	  or	  samples	  13	  and	  14	  of	  the	  frontal	  cortex	  but	  all	  the	  samples	  were	  normalized	  and	  adjusted	  to	  the	  levels	  of	  β-­‐actin	  (Fig	  6/7.A).	  	  	  For	   each	   brain	   region	   a	   series	   of	   Western	   blots	   were	   prepared	   and	   immunostained	   with	  antibodies	   for	   GFAP,	   AD2	   and	   β-­‐amyloid	   to	   asses	   the	   degree	   respectively	   of	   astrogliosis,	  pathological	  tau	  protein	  and	  amyloid	  plaques.	  Antibodies	  directed	  against	  TNF-­‐α,	  NF-­‐kB	  and	  IL-­‐1β	   –	   three	   molecules	   having	   an	   important	   role	   in	   the	   cascade	   of	   reactions	   triggered	   by	  inflammatory	   cells	   -­‐	  were	   used	   to	   highlight	   inflammatory	   processes.	   The	   samples	   are	   aligned	  from	  left	  to	  right	  starting	  with	  the	  control	  group	  and	  then	  the	  AD	  cases.	  Patients	  9	  to	  14	  of	  the	  entorhinal	   cortex	   (Fig	   6)	   and	   patients	   8	   to	   13	   of	   the	   frontal	   cortex	   (Fig	   7)	  were	   identified	   as	  cases	  of	  moderate	  Alzheimer’s	   disease	   (Braak	   stages	   II	   to	   IV).	   The	   rest	   of	   the	  AD	  patients	   are	  cases	  of	  severe	  AD	  (Braak	  stages	  V	  to	  VI).	  	  	  GFAP	   immunoreactivity	   in	   the	   entorhinal	   cortex	   (Fig	   6.C)	   is	   present	   everywhere	  with	   a	   trend	  towards	   increased	   GFAP	   immunoreactivity	   in	   moderate	   AD	   cases.	   However,	   the	   more	   the	  disease	  progresses	  (severe	  AD	  group)	  the	  more	  the	  detection	  of	  GFAP	  seems	  to	  fade.	  The	  results	  obtained	  in	  the	  frontal	  cortex	  (Fig	  7.C)	  are	  more	  difficult	  to	  interpret	  on	  the	  immunoblot,	  which	  seems	  very	  homogeneous	  although	  the	  results	  suggest	  a	  slight	  increase	  of	  the	  GFAP	  detection	  in	  the	  severe	  AD	  group.	  	  	  The	  immunodetection	  by	  AD2	  (Fig	  6/7.D)	  -­‐	  a	  monoclonal	  antibody	  directed	  against	  pathological	  hyperphosphorylated	   tau	   proteins	   -­‐	   shows	   no	   detection	   in	   the	   control	   tissues,	   except	   for	   two	  controls	  in	  the	  entorhinal	  cortex	  where	  we	  can	  distinguish	  a	  slight	  detection	  for	  patients	  7	  and	  8.	  In	  contrast,	  tissues	  from	  patients	  with	  Alzheimer’s	  disease	  show	  a	  large	  disparity	  of	  results	  with	  a	  significant	  increase	  of	  AD2	  levels	  in	  the	  severe	  AD	  group	  in	  both	  brain	  regions.	  	  	  Results	   with	   monoclonal	   β-­‐amyloid	   antibody	   vary	   somewhat	   between	   the	   two	   brain	   regions	  studied.	   In	   the	   entorhinal	   cortex	   (Fig	   6.E),	   the	   immunoreactivity	   reflects	   a	   distribution	   of	   β-­‐amyloid	   to	   all	   samples,	   controls	   and	   AD	   patients,	   with	   however	   a	   significant	   decrease	   of	   the	  immunoreactivity	  in	  the	  AD	  cases.	  The	  results	  obtained	  in	  the	  frontal	  cortex	  (Fig	  7.E)	  are	  almost	  the	  opposite	  suggesting	  an	  increment	  of	  this	  protein	  in	  AD	  cases	  with	  a	  more	  significant	  increase	  in	  the	  severe	  Alzheimer	  group.	  	  The	   amyloid	   detection	   is	   at	   about	   100	   kDa,	   which	   could	   indicate	   that	   the	   antibody	   used	  recognizes	   the	   amyloid	   precursor	   protein	   that	   is	   about	   90	   kDa	   and	   not	   the	   Aβ	   fragment.	   The	  cleavage	  of	   β-­‐amyloid	  precursor	  protein	   (APP)	   generates	  multiple	  proteins,	   soluble	  β-­‐amyloid	  precursor	  protein	  alpha	  and	  beta	  (sAPPα,	  sAPPβ)	  and	  Aβ	  peptide.	  Previous	  studies	  have	  shown	  that	   sAPPα	   and	   sAPPβ	   possess	   neurotrophic	   properties,	   whereas	   Aβ	   is	   neurotoxic	   [72].	   The	  detection	   here	   could	   be	   the	   neurotrophic	   part	   of	   the	   APP,	   the	   sAPPalpha	   or	   the	   sAPPbeta	  proteins.	   This	   could	   explain	   the	   decrease	   observed	   in	   cases	   of	   Alzheimer's	   disease	   of	   the	  entorhinal	  cortex	  [72].	  	  The	   three	   antibodies	   used	   for	   the	   detection	   of	   specific	   inflammatory	   molecules	   show	   rather	  homogeneous	  results	  and	  will	  be	  discussed	  as	  one	  inflammatory	  process.	  The	  entorhinal	  cortex	  (Fig	  6.F-­‐H)	  does	  not	  appear	   to	  show	  an	   increase	   in	   inflammation	   in	   the	  AD	  cases	  compared	  to	  control	   ones.	   On	   the	   contrary,	   the	   results	   suggest	   rather	   a	   decrease	   in	   inflammatory	   proteins	  with	  the	  progression	  of	  the	  disease.	  On	  the	  other	  hand,	  the	  results	  obtained	  in	  the	  frontal	  cortex	  (Fig	   7.F-­‐H)	   show	   an	   increase	   of	   the	   immunosignal	  with	   the	   development	   of	   the	   disease.	   This	  increase	  is	  even	  more	  important	  in	  cases	  with	  severe	  AD.	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FIG.%6:!One*DE%gels%3.6*15%%gradient%gels%
with% 20µg% of% entorhinal% cortex% sample%
per%well.!!!
The$ first$8$are$controls$without$neurological$
pathology.$ The$ next$ 11$ samples$ are$ the$ AD$
patients.$ This$ group$ is$ separated$ into$ two$
other$ groups,$ the$ first$ 6$ samples$ are$
moderate$AD$and$the$last$5$are$severe$AD.$All$
the$ samples$were$normalized$ to$ the$ levels$of$
βAactin$(A).$The$samples$were$then$prepared$
for$Coomassie$blue$stain$(B)$and$for$Western$
blots$ immunostained$ with$ (C):$ polyclonal$
antiAGFAP;$ (D):$ monoclonal$ antiAAD2;$ (E):$
monoclonal$ antiA“βAamyloid”;$ (F):$
monoclonal$ antiATNFAα;$ (G):$ monoclonal$
antiANFAkB;$(H):$monoclonal$antiAILA1β.$After$
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9.	  Statistical	  analyses	  and	  proteins	  quantification	  
	  
9.1	   Analysis	   of	   inflammation	   according	   to	   the	   stage	   of	   the	   disease	   and	   to	   the	   cerebral	  
distribution	  between	  the	  entorhinal	  and	  the	  frontal	  cortex.	  	  
	  In	   order	   to	   know	  whether	   inflammation	   is	   found	   significantly	   in	   patients	   with	   AD,	   the	   three	  groups	  were	  compared	  with	  each	  other	  for	  each	  cerebral	  region	  by	  the	  One	  way	  Anova	  test.	  The	  antibodies	  used	  to	  detect	   the	   inflammation	  are	  GFAP	  for	   the	  reactive	  gliosis,	  TNF-­‐α,	   IL-­‐1β	  and	  NF-­‐κB.	  The	  test	  attempts	  to	  reject	  the	  null	  hypothesis,	  which	  states	  that	  the	  three	  groups	  have	  the	  same	  inflammatory	  composition.	  In	  case	  of	  rejection	  of	  the	  null	  hypothesis	  the	  three	  groups	  were	   compared	   in	   pairs	  with	   the	  Posthoc	  Tukey’s	   test.	   The	   threshold	   for	   rejection	   of	   the	   null	  hypothesis	  is	  a	  p-­‐value	  <	  0.05.	  	  
Entorhinal	  Cortex	  	  With	  this	  analysis	  it	  is	  possible	  to	  reject	  the	  null	  hypothesis	  for	  IL-­‐1β,	  β-­‐amyloid	  and	  AD2	  in	  the	  entorhinal	  cortex	  and	  identify	  a	  significant	  difference	  in	  the	  levels	  of	  these	  markers	  between	  the	  three	  groups.	  	  The	  FIG.8	  shows	  the	  distribution	  of	  astrocytes	  and	  inflammation	  according	  to	  the	  severity	  of	  the	  disease	  in	  the	  entorhinal	  cortex.	  The	  analysis	  identifies	  a	  significant	  difference	  in	  the	   proteins	   composition	   between	   the	   three	   groups	   only	   for	   IL-­‐1β	  with	   less	   quantities	   of	   this	  protein	  in	  the	  group	  with	  severe	  AD	  compared	  within	  the	  two	  other	  groups	  (p-­‐value	  =	  0.00507).	  The	  data	  available	  do	  not	  provide	   sufficient	   evidence	   that	   the	  other	  markers	  are	  differentially	  expressed	  between	  the	  three	  groups	  (p-­‐value	  >	  0.05).	  The	  FIG.9	  shows	  the	  distribution	  of	  AD2	  and	  β-­‐amyloid	  according	   to	   the	   severity	  of	   the	  disease	   in	   the	  entorhinal	   cortex.	  The	   statistical	  analysis	  identifies	  a	  significant	  difference	  in	  the	  proteins	  composition	  between	  the	  three	  groups.	  (p-­‐value	  <	  0.05).	  The	  analysis	  of	  AD2	   immunoreaction	  allows	  stating	   that	  patients	  with	  severe	  AD	  have	  higher	  AD2	  levels	  than	  those	  with	  moderate	  AD	  or	  without	  the	  disease	  and	  that	  patients	  with	  moderate	  AD	  have	  higher	  AD2	   levels	   than	   the	   controls.	  The	  β-­‐amyloid	  analysis	   allows	   to	  state	   that	   patients	  with	   severe	  AD	  have	   less	   amyloid	   amounts	   than	   the	   two	  other	   groups	   and	  that	  patient	  with	  moderate	  AD	  have	  less	  amyloid	  amounts	  than	  the	  control	  group.	  	  	  
	  	  
FIG.% 8:% Immunoreaction% intensity% of% markers% for%
astrocytes% and% in7lammation% according% to% the%





















!!!!!!!**! FIG.% 9:% Immunoreaction% intensity% of% markers% for%
AD2%and%βAamyloid%according%to%the%severity%of%the%
disease%in%the%entorhinal%cortex.%%
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Frontal	  Cortex	  	  In	   the	   frontal	   cortex	   the	   statistical	   analyses	   allow	   rejecting	   the	   null	   hypothesis	   for	   GFAP,	   β-­‐amyloid	  and	  AD2	  and	  to	  highlight	  a	  significant	  difference	  in	  the	  levels	  of	  these	  markers	  between	  the	  three	  groups.	  The	  FIG.10	  shows	  the	  distribution	  of	  astrocytes	  and	  inflammation	  according	  to	  the	  severity	  of	  the	  disease	  in	  the	  frontal	  cortex.	  The	  analysis	  identifies	  a	  significant	  difference	  in	  the	   proteins	   composition	   between	   the	   three	   groups	   only	   for	   GFAP	   with	   higher	   levels	   of	   this	  protein	  in	  the	  severe	  AD	  group	  compared	  to	  the	  other	  ones	  (p-­‐value	  =	  0.016).	  The	  data	  available	  do	   not	   provide	   sufficient	   evidence	   to	   state	   that	   the	   inflammatory	   markers	   are	   differentially	  expressed	  between	  the	  three	  groups	  (p-­‐value	  >	  0.05).	  The	  FIG.11	  shows	  the	  distribution	  of	  AD2	  and	   β-­‐amyloid	   according	   to	   the	   severity	   of	   the	   disease	   in	   the	   frontal	   cortex.	   It	   is	   possible	   to	  identify	  a	  significant	  difference	  in	  the	  proteins	  composition	  between	  the	  three	  groups.	  (p-­‐value<	  0.05).	  The	  AD2	  analysis	  allows	  stating	  that	  patients	  with	  severe	  AD	  have	  higher	  AD2	  levels	  than	  those	  moderate	  AD	  or	  without	   the	  disease.	  The	  β-­‐amyloid	  analysis	  allows	  stating	  that	  patients	  with	  severe	  AD	  have	  higher	  amyloid	  amounts	  than	  the	  two	  other	  groups.	  	  	  
	  	  
FIG.% 8:% Immunoreaction% intensity% of% markers% for%
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FIG.% 10:% Immunoreaction% intensity% of%markers% for%
astrocytes% and% in7lammation% according% to% the%
severity%of%the%disease%in%the%frontal%cortex.%%




FIG.% 11:% Immunoreaction% intensity% of%markers% for%
AD2%and%βAamyloid%according%to%the%severity%of%the%
disease%in%the%frontal%cortex.%%
%Statistical!analysis!by!the!One!Way!Anova!test!of!AD2!and!β:amyloid!between! severe!AD,!moderate!AD!and!controls.!!!The!values!on!the!left!represent!the!staining!density!of!immunoblotting!bands.!One!asterisk!means! there! is!a!statistical! signiIicance! (p! <! 0.05)! while! very! high!statistical!signiIicance!(p!<!0.01)!is!reported!with!two!asterisks.!!!!!
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10.	  Summary	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  results	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FIG.%12:%Distribution%of%in7lammation%according%to%the%age%of%subject.%!Statistical!analysis!by!the!Kendall's!tau!correlation!coefIicient!of!the!association!between!the!age!of!subjects!and!the!values!of!inIlammatory!markers.!No!statistical!correlation!was!found!and!the!p:value!was!>!0.05!for!the!three!proteins.!!!!!!
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they	   become	   more	   important	   with	   the	   progression	   of	   it	   in	   the	   frontal	   cortex	   but	   that	   they	  diminishes	  in	  the	  entorhinal	  region	  when	  the	  disease	  reaches	  a	  severe	  stage.	  	  
	  
	  
11.	  Discussion	  	  
Inflammation	  and	  Alzheimer’s	  disease	  	  	  The	  purpose	  of	  the	  present	  study	  was	  to	  corroborate	  the	  hypothesis	  that	  the	  pathogenesis	  of	  AD	  is	  also	  accompanied	  by	  a	  reactive	  gliosis	  supporting	  the	  idea	  that	  inflammatory	  processes	  occur	  in	  some	  brain	  regions.	  The	  results	  obtained	  in	  this	  study	  suggest	  that	  immune	  responses	  in	  the	  central	  nervous	  system	  play	  a	  role	  in	  the	  early	  development	  of	  Alzheimer’s	  disease	  but	  it	  seems	  that	  the	  worsening	  of	  cognitive	  symptoms	  is	  associated	  to	  other	  components.	  	  	  The	   increase	   in	  glial	   fibrillary	  acidic	  protein,	  GFAP,	   is	  a	  well-­‐established	  feature	  of	  Alzheimer’s	  disease	  and	  serves	  as	  a	  good	  marker	  to	  indicate	  neurodegenerative	  changes	  [39,	  45,	  47,	  49,	  52,	  73]	  The	  analysis	  of	  this	  study	  confirms	  that	  it	  is	  an	  important	  component	  at	  the	  beginning	  of	  the	  disease	  showing	  that	  GFAP	  levels	  are	  very	  high	  in	  the	  moderate	  AD	  group.	  The	  evolution	  of	  this	  protein	   varies	   however	   according	   to	   the	   progression	   of	   the	   disease	   and	   brain	   region.	   For	  example,	  in	  the	  entorhinal	  cortex	  the	  more	  the	  disease	  advances	  the	  more	  GFAP	  levels	  seem	  to	  lose	   their	   importance.	   The	   results	   of	   a	   previous	   study	   based	   on	   an	   immune	   therapy	   are	   in	  accordance	   with	   these	   findings	   showing	   a	   decline	   of	   active	   microglia	   levels	   in	   patients	   with	  severe	  AD	  and	  thus	  highlighting	  the	  possibility	  of	  a	  reduction	  of	  the	  reactive	  gliosis	  in	  the	  later	  stages	  of	  the	  disease	  [57].	  On	  the	  other	  hand,	  the	  frontal	  cortex	  shows	  an	  increase	  in	  this	  protein	  density	   with	   the	   progression	   of	   cognitive	   decline.	   According	   to	   Braak	   and	   colleagues,	  Alzheimer’s	  disease	  starts	  in	  a	  region	  of	  the	  temporal	  lobe,	  which	  includes	  the	  hippocampus	  and	  the	  entorhinal	  cortex	  and	  spreads	  to	  the	  rest	  of	  the	  brain	  areas,	  particularly	  in	  the	  frontal	  cortex,	  only	  later	  in	  time	  [28].	  We	  can	  therefore	  assume	  that	  while	  the	  disease	  reaches	  a	  very	  advanced	  stage	   in	   the	   entorhinal	   cortex	   –	  when	   all	   the	   neurons	   are	   dead	   and	   the	   glia	   seems	   not	   active	  anymore	  -­‐	  it	  progresses	  in	  the	  frontal	  cortex	  where	  active	  neurodegeneration	  and	  astrocytes	  can	  be	   found	   in	  great	  quantities.	  This	  observation	   is	   in	   agreement	  with	   the	   study	  of	  Porchet	   et	   al.	  suggesting	  an	  association	  between	   the	  degree	  of	  neuronal	  death	  and	   the	  amount	  of	  astrocytes	  [39].	  Glial	  cells	  are	   the	  protectors	  of	   the	  central	  nervous	  system	  and	  among	  all	   their	   functions	  they	  have	  the	  capacity	  to	  respond	  to	  all	  forms	  of	  brain	  injury	  by	  transforming	  to	  an	  active	  state	  and	   secreting	   pro-­‐inflammatory	   cytokines	   [45,	   52,	   73].	   These	   reactions	   are	   a	   normal	  physiological	  response	  of	  the	  body	  against	  external	  or	  internal	  aggression	  and	  can	  therefore	  also	  be	  encountered	  during	  normal	  aging	  [39].	  This	  might	  explain	  why	  of	  GFAP	  was	  also	  found	  in	  the	  control	  group.	  	  	  However,	  this	  ability	  of	  immune	  cells	  to	  activate	  themselves	  and	  to	  secrete	  cytokines	  to	  protect	  the	   brain	   from	   aggressions	   can	   also	   have	   deleterious	   effects	   and	   play	   a	   key	   role	   in	   the	  pathogenesis	   of	   neurodegenerative	   diseases.	   Indeed,	   astrocytes	   and	   microglia,	   the	   major	  immune	  cells	   in	   the	  cerebral	   tissue,	  are	   involved	   in	   the	  maintenance	  of	   the	  synaptic	  plasticity,	  which	  allows	  the	  modulation	  of	  connections	  between	  neurons	  [47,	  74].	  This	  neural	  plasticity	  is	  essential	  to	  the	  development	  of	  learning	  and	  memory	  and	  allows	  explaining	  the	  many	  forms	  of	  memory	  present	  in	  all	  individuals	  with	  a	  central	  nervous	  system	  [75,	  74].	  This	  fine	  and	  precise	  modulation	  of	  neuronal	  connections	  is	  achieved	  through	  these	  same	  proinflammatory	  cytokines	  such	   as	   TNF-­‐α	   and	   IL-­‐1β	   [74].	   During	   neurodegeneration,	   the	   immune	   cells	   involved	   secrete	  larger	   amounts	   of	   cytokines,	   which	   consequently	   alters	   the	   normal	   and	   necessary	   balance	   to	  maintain	   synaptic	   plasticity	   [74].	   Thus,	   neuroinflammation	   could	   also	   participate	   in	   the	  pathogenesis	   of	   neurodegenerative	   diseases	   by	   altering	   the	   synaptic	   processes	   that	   underlie	  learning	  and	  memory.	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A	   number	   of	   studies	   also	   demonstrated	   that	   highly	   toxic	   products	   such	   as	   reactive	   oxygen	  intermediates	  and	   inflammatory	  cytokines	  such	  as	  TNF-­‐α	  and	  IL-­‐1β	  produced	  and	  secreted	  by	  astrocytes	  might	  induce	  a	  subsequent	  cascade	  of	  pro-­‐inflammatory	  gene	  transcription	  that	  can	  lead	  to	  neuronal	  loss	  [42,	  48,	  55,	  65,	  76].	  Inflammation	  plays	  an	  important	  role	  in	  brain	  injuries	  by	  decreasing	   the	  permeability	  of	   the	  blood-­‐brain	  barrier	  allowing	  changes	   in	   the	  cellular	  and	  inflammatory	   profile	   of	   the	   brain	   tissue	   [55].	   Chronically	   activated	   immune	   cells	   and	  inflammatory	  cytokines	  are	  then	  believed	  to	  play	  a	  central	  role	  on	  neurodegenerative	  disorders	  by	   inducing	   neuronal	   death	   [49].	   The	   results	   of	   the	   present	   study	   are	   compatible	   with	   that	  hypothesis	   revealing	   a	   similar	   evolution	   between	   GFAP	   and	   inflammatory	   molecules	   in	   AD	  brains.	  It	  also	  revealed	  that	  in	  the	  entorhinal	  cortex	  neuroinflammation	  is	  very	  important	  in	  the	  moderate	  AD	  group,	  with	  high	  levels	  of	  TNF-­‐α,	  IL-­‐1β	  and	  NF-­‐kB,	  while	  it	  decreases	  in	  the	  severe	  AD	  group	  when	  the	  amount	  of	  astrocytes	  diminishes.	  The	  inflammatory	  components	  also	  follow	  the	  same	  increasing	  trend	  as	  GFAP	  in	  the	  frontal	  cortex	  when	  the	  disease	  spreads	  into	  that	  brain	  area.	   In	   agreement	  with	   the	   idea	   that	   the	  evolution	  observed	   in	   the	   frontal	   cortex	   reflects	   the	  earlier	  events	   that	  occurred	  previously	   in	   the	  entorhinal	   area,	   the	   results	   show	  an	   increase	  of	  the	   inflammatory	   components	   in	   this	   brain	   area.	   This	   observation	   again	   strongly	   suggests	   an	  early	   involvement	   of	   inflammatory	   processes	   in	   the	   pathogenesis	   of	   AD.	   These	   results	   are	   in	  agreement	  with	  many	   studies	   that	   also	  highlighted	   the	   role	  of	   immune	   responses	   in	   the	   early	  stages	  of	  the	  disease	  [39,	  40,	  76,	  77,	  78].	  	  	  Inflammation	  could	  also	  play	  a	  role	  as	  a	  potential	  mediator	  of	  oxidative	  stress	  and	  dysfunction	  of	  the	  ubiquitin	  proteasome	  system	  [55].	  The	  main	  function	  of	  this	  ubiquitin	  proteasome	  complex	  is	   to	   control	   and	   to	   degrade	   unneeded	   or	   damaged	   proteins.	   The	   toxicity	   of	   inflammation	   is	  principally	  mediated	  by	  the	  release	  of	  reactive	  oxygen	  and	  reactive	  nitrogen	  species	  by	  glial	  cells	  as	   a	   defence	   mechanism	   against	   injury	   or	   neurodegeneration	   [49].	   Unfortunately,	   these	   free	  radicals	   can	   cause	   severe	   alterations	   in	   the	   structure	   and	   function	   of	   proteins	   leading	   to	   a	  dysfunction	  of	   the	  proteasome	  system	  and	  to	  neuronal	  cells	  death	  [42,	  55].	   It	  has	   indeed	  been	  shown	   that	   alterations	   of	   the	   oxidative	   processes	   and	   the	   formation	   of	   excess	   free	   radicals	  during	  neuroinflammation	  can	   lead	   to	  cellular	  dysfunctions	  and	  may	  play	  a	  pathogenic	   role	   in	  early	   AD	   [55,	   65].	   Thus	   in	   Alzheimer’s	   disease	   aggregation	   of	   abnormal	   proteins	   could	   be	  induced	  by	  an	  activation	  of	   inflammatory	  processes,	  reactive	  gliosis	  and	  oxidative	  damage	  [42,	  49].	  	  	  As	  mentioned	  in	  several	  studies	  the	  inflammatory	  and	  oxidative	  characteristics	  of	  AD	  may	  also	  be	   present	   during	   normal	   aging	   [49,	   50,	   53,	   55,	   65].	   The	   status	   of	   oxidative	   processes	   and	  inflammation	   can	   be	   modified	   by	   the	   normal	   senescence	   and	   normal	   cells	   degeneration	   also	  leading	  to	  a	  cellular	  and	  ubiquitin	  proteasome	  system	  dysfunction	  [42,	  55,	  65].	  In	  addition,	  the	  antioxidant	   defence	   mechanisms	   decrease	   during	   normal	   aging	   with	   a	   consequent	   failure	   to	  repair	   and	   degrade	   damaged	   proteins	   [55].	   The	   present	   study	   corroborates	   these	   overlap	  between	  normal	  and	  pathological	  aging	  with	  similar	  results	  between	  the	  control	  group	  and	  the	  ones	   affected	   by	   the	   disease.	   These	   similarities	  make	   it	   even	  more	   difficult	   to	   understand	   the	  pathological	  processes	  of	  Alzheimer's	  disease.	  More	  over,	  clinical	  trials	  using	  these	  inflammatory	  and	  oxidative	  processes	  as	  therapeutic	  strategies	  in	  AD	  have	  not	  yielded	  convincing	  results	  [54,	  56,	  57,	  64,	  79]	  
	  
Pathological	  hallmarks	  of	  Alzheimer’s	  disease:	  beta-­‐amyloid	  and	  neurofibrillary	  tangles	  	  The	   deregulation	   of	   the	   APP	   metabolism	   and	   therefore	   the	   deposition	   of	   senile	   plaques,	   in	  particular	  beta-­‐amyloid	  protein,	   have	  been	  assumed	   to	  have	   a	   toxic	   effect	   on	   the	   surrounding	  cells	  and	  thereby	  be	  potent	  activators	  of	  the	  innate	  immune	  responses	  [30,	  65,	  80].	  These	  senile	  plaques	  are	  supposed	  to	  have	  a	  crucial	  role	  in	  the	  development	  of	  the	  disease	  and	  to	  be	  closely	  related	   to	   neuroinflammation	   [40].	   Morales	   and	   colleagues	   demonstrated	   that	   endogenous	  damage	  signals	  –	  probably	  the	  senile	  plaques	  –	  can	  activate	  microglia	  and	  astrocytes,	   inducing	  NF-­‐kB	  with	  consequent	  release	  of	  cytokines	  mediators	  such	  as	  TNF-­‐α	  and	  IL-­‐1β	  [81].	  The	  well-­‐
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established	  association	  of	  glial	  cells	  and	  inflammation	  related	  proteins	  around	  amyloid	  plaques	  reinforce	  this	  hypothesis	  [39,	  42,	  65].	  In	  the	  present	  study,	  the	  results	  of	  the	  β-­‐amyloid	  protein	  corroborate	  this	  idea	  revealing	  a	  quite	  similar	  evolution	  of	  its	  density	  to	  that	  of	  GFAP.	  First,	  they	  show	  that	  Aβ	  density	  is	  higher	  at	  the	  onset	  of	  the	  disease,	  e.g.	  among	  the	  moderate	  AD	  patients.	  Second,	  it	  seems	  that	  the	  amount	  of	  protein	  amyloid	  in	  the	  entorhinal	  cortex	  decreases	  with	  the	  progression	   of	   the	   disease	   as	  well	   as	  GFAP	   levels.	   These	   observations	   are	   consistent	  with	   the	  results	  published	  by	  Costanza	  and	  colleagues	  [30],	  which	  showed	  that	  levels	  of	  amyloid	  deposits,	  detected	  by	  positron	  emission,	  increase	  rapidly	  at	  the	  beginning	  of	  the	  degenerative	  process	  but	  seem	   to	   stabilize	   and	   reach	   a	  plateau	  when	   the	  disease	  progresses	   and	   the	   clinical	   symptoms	  appear.	   Then,	  when	   the	  disease	   reaches	   a	  more	   advanced	   state,	   the	   density	   of	   the	  Aβ	   protein	  appears	  to	  be	  very	   little	  associated	  with	  the	  evolution	  of	   the	  cognitive	  decline	  [81].	  Finally	  the	  frontal	  cortex,	  later	  hit	  by	  the	  disease,	  also	  follows	  the	  same	  trend	  as	  GFAP	  showing	  an	  increase	  in	  the	  amyloid	  density	  with	  the	  progression	  of	  the	  disease.	  It	  can	  be	  assumed	  that	  this	  region	  is	  reaching	  the	  plateau	  observed	  by	  Costanza	  et	  al.	  and	  that	  subsequently	  the	  levels	  of	  β-­‐amyloid	  will	  also	  begin	  to	  decrease.	  This	  corroborates	  the	  hypothesis	  suggested	  by	  several	  studies	  that	  although	   Aβ	   deposits	  may	   play	   a	   key	   role	   in	   the	   neuronal	   death	   and	   the	   reactive	   gliosis,	   the	  severity	  of	  cognitive	  decline	  in	  the	  advanced	  stages	  of	  the	  disease	  may	  be	  very	  loosely	  bound	  to	  the	  amyloid	  load	  [30,	  38,	  81,	  82].	  As	  the	  other	  proteins,	  the	  amyloid	  components	  are	  also	  found	  in	   the	   control	   group	   providing	   the	   evidence	   that	   all	   these	   pathological	   hallmarks	   can	   also	   be	  present	  during	  normal	  aging.	  This	  statement	  was	  already	  suggested	  by	  many	  other	  studies	  [30,	  37,	   81],	   which	   revealed	   a	   significant	   overlap	   between	   controls	   and	   patients	   with	   AD	  making	  more	  difficult	  to	  underlie	  the	  exact	  pathological	  hallmarks	  and	  the	  molecular	  pathways	  leading	  to	  the	  disease.	  	  This	   Aβ	   hypothesis	   also	   suggested	   that	   the	   amyloid	   protein	   may	   be	   the	   first	   trigger	   of	   the	  Alzheimer	   pathological	   cascade.	   However,	   as	   mentioned	   earlier,	   amyloid	   density	   is	   inversely	  proportional	   to	   the	   severity	   of	   the	   cognitive	   decline.	   Some	   studies	   pointed	   that	   total	  neurofibrillary	   tangles	   (NFT)	   counts	   may	   be	   more	   strongly	   associated	   to	   neuronal	   loss	   than	  amyloid	  amounts	  [30,	  55,	  81,	  82].	  The	  presence	  of	  these	  aggregates	  of	  abnormal	  tau	  molecules	  in	  AD	   brains	   has	   indeed	   been	   widely	   described	   in	   literature	   and	   these	   studies	   suggest	   that	   tau	  density	  would	  be	  better	  correlated	  with	   the	  symptoms	  of	   the	  disease	   than	  the	  presence	  of	   the	  amyloid	   burden	   [30,	   38,	   81].	   The	   results	   obtained	   in	   this	   study	   also	   corroborate	   these	  observations	  showing	  an	  increasing	  evolution	  in	  the	  two	  brain	  regions	  of	  the	  AD2	  antibody	  with	  the	   progression	   of	   the	   disease	   being	   first	   very	   low	   in	   the	   moderate	   AD	   group	   to	   finally	  significantly	   increase	   in	   the	  group	  with	  severe	  AD.	  Although	  amyloid	  deposits	  and	  astrogliosis	  have	  been	  clearly	  demonstrated	  in	  the	  brain	  of	  patients	  suffering	  from	  AD	  [30,	  39,	  42,	  65,	  80],	  it	  appears	   that	   NFT	   is	   an	   event	   more	   strongly	   associated	   with	   neuronal	   loss	   and	   clinical	  manifestation	  of	  the	  disease	  than	  the	  amyloid	  amounts.	  	  	  The	   link	   between	   these	   different	   assumptions	   underlying	   the	   etiology	   of	   the	   disease	   –	   tau	  protein,	  beta-­‐amyloid	  and	   inflammation	  –	  has	  not	  yet	  been	  clearly	  elucidated	  and	  needs	   to	  be	  further	  explored.	  Some	  evidences	  suggested	  however	  that	  the	  Aβ	  and	  its	  inflammatory	  cascade	  might	   precede	   the	   development	   of	   both	   NFT	   formation	   and	   cognitive	   impairment	   [77].	   As	  presented	  in	  a	  study	  the	  amyloid	  deposits	  may	  activate,	  in	  addition	  to	  astrocytes	  and	  microglia,	  some	   caspases,	   essential	   proteases	   in	   cell	   death,	   which	   in	   consequence	   may	   lead	   to	   the	  disruption	  of	   the	  nuclear	   cytoskeletal	   components	   such	   as	   tau	  protein	   [38].	   This	  may	   then	  be	  critical	   to	  NFT	   formation	  and	   to	   the	   clinical	  progression	  of	  dementia.	  Other	  neuropathological	  studies	   also	   highlighted	   that	   a	   neuroinflammatory	   response	   in	   the	   cerebral	   neocortex	   could	  parallel	  the	  early	  stages	  of	  AD	  pathology	  and	  precedes	  the	  late	  stage,	  tau-­‐related	  pathology	  [15].	  More	  over	  it	  is	  supposed	  that	  amyloid	  deposition	  begins	  10	  to	  20	  years	  before	  the	  appearance	  of	  clinical	  dementia	  [40].	  A	  study	  published	  in	  1998	  had	  already	  highlighted	  this	  feature	  of	  the	  very	  advanced	  stages	  of	  Alzheimer's	  disease.	  Indeed,	  Thal	  and	  colleagues	  had	  noticed	  in	  the	  terminal	  stages	  of	  the	  disease,	  that	  the	  frequency	  of	  plaques	  was	  significantly	  reduced	  while	  a	  progressive	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increased	   in	  alteration	  of	   tau	  protein	  could	  be	  correlated	   to	  a	  sharp	  deterioration	   in	  dementia	  [83].	   The	   results	   of	   the	   present	   study	   do	   confirm	   this	   concept	   of	   evolution	   of	   the	   Alzheimer	  pathogenesis.	   The	   amyloid	   deposition	   and	   the	   inflammatory	   components	   seem	   to	   start	   very	  early	   in	   the	  disease,	  perhaps	  even	  before	   the	  appearance	  of	   the	   first	   symptoms,	   suggesting	  an	  initial	   role	   of	   these	  proteins	   in	   the	  disease.	   Then	   as	   the	  density	   of	  Aβ	   and	  neuroinflammation	  seem	  to	  stabilize	  and	  to	  decrease,	  the	  quantities	  of	  tau	  protein	  increase	  and	  the	  symptoms	  of	  the	  disease	  worsen	  with	  more	  important	  deterioration	  of	  cognitive	  decline.	  	  	  The	  results	  also	  show	  a	  slight	  signal	  of	  AD2	  on	  the	  control	  group.	  This	  may	  be	  the	  evidence	  that	  the	  hyperphosphorylation	  of	  tau	  protein	  may	  also	  be	  encountered	  during	  normal	  aging,	  as	  is	  the	  case	   of	   the	   other	   components,	   and	   that	   these	   pathological	   characteristics	   may	   then	   not	   be	  unique	  to	  dementia.	  These	  observations	  are	  in	  agreement	  with	  many	  studies,	  which	  highlighted	  that	  NFT	  and	  amyloid	  deposits	   are	   also	  observed	   in	  normal	   aging	   [15,	   27,	   35,	   55,	   65,	   81,	   82].	  Giannakopoulos	  and	  his	  colleagues	  pointed	  out	   that	   in	  case	  of	  AD	  the	  distribution	   in	   the	  brain	  areas	   and	   the	   respective	   densities	   of	   these	   components	   are	   significantly	   different	   and	   more	  abundant	  than	  in	  normal	  aging	  brains	  [82].	  This	  pathological	  cascade	  suggests	  that	  AD	  may	  be	  due	  to	  several	  factors	  that	  in	  relationship	  with	  each	  other	  could	  lead	  to	  the	  neurodegenerative	  processes	  and	  to	  the	  severe	  cognitive	  impairment.	  	  Although	   research	   has	   permitted	   to	   highlight	   some	   of	   the	   characteristics	   underlying	   the	  neurodegeneration,	   the	   exact	   cause	   of	   AD	   remains	   unknown.	   In	   addition,	   the	   role	   of	  neuroinflammation	   is	   still	   not	   well	   understood.	   Indeed,	   it	   is	   not	   clear	   whether	  neurodegeneration	  could	  be	  caused	  by	  neuroinflammation	  or	  if	  this	   immune	  cascade	  may	  only	  be	  a	  reflection	  of	  a	  desperate	  attempt	  to	  repair	  brain	  cell	  damage.	  This	  study	  allows	  however	  to	  corroborate	   some	   hypothesis	   already	   presented	   in	   the	   past	   and	   to	   focus	   on	   the	   role	   of	  inflammation	   including	   proinflammatory	   cytokines	   such	   as	   TNF-­‐α,	   IL-­‐1β	   and	   NF-­‐κB	   in	  association	   with	   a	   reactive	   gliosis	   at	   the	   beginning	   of	   the	   disease.	   It	   also	   highlighted	   the	  significant	   difference	   between	   brain	   regions	   with	   a	   probable	   onset	   of	   the	   disease	   in	   the	  entorhinal	  region,	  as	  described	  by	  Braak	  and	  Braak	  in	  the	  90s	  [28]	  and	  similar	  but	  later	  changes	  in	  the	  frontal	  cortex	  and	  probably	  also	  in	  other	  brain	  regions.	  	  It	   is	  however	   important	   to	  note	   that	   this	   study	   is	   limited	   to	  a	   small	  number	  of	   samples	  and	   it	  would	   be	   wise	   to	   conduct	   a	   similar	   study	   on	   a	   larger	   scale	   by	   including	   a	   larger	   number	   of	  patients	   in	   order	   to	   draw	  more	   significant	   conclusions.	   In	   this	   study	   TNF-­‐α,	   IL-­‐1β	   and	  NF-­‐κB	  were	   used	   as	   inflammatory	   cytokines	   but	   many	   other	   components	   of	   neuroinflammation	   are	  also	  very	  important	  and	  it	  would	  be	  judicious	  to	  use	  other	  markers	  of	  inflammation	  such	  as	  for	  example	  IL-­‐6,	  INF-­‐γ,	  the	  C-­‐reactive	  protein	  or	  the	  complement.	  	  
	  
	  
12.	  Conclusions	  and	  Perspectives	  	  Alzheimer’s	  disease	   represents	   a	  major	  public	  health	   concern	  not	  only	  by	   its	   frequency	   in	   the	  world	  population	  but	  also	  by	  its	  ambiguous	  relationship	  with	  the	  physiology	  of	  normal	  aging.	  It	  has	   indeed	  been	  highlighted	   that	   the	   characteristic	   features	  of	   this	  disease	  are	  also	  present	   in	  normal	  brain	  in	  most	  of	  the	  elderly	  after	  70	  in	  the	  absence	  of	  cognitive	  decline	  [30].	  It	  has	  also	  been	  established	  now	  that	  age	   is	   the	  biggest	   risk	   factor	   for	  non-­‐genetic	  AD	  [30].	   It	   is	  however	  presently	  not	  well-­‐understood	  why	  and	  the	  similarities	  of	  this	  disease	  with	  normal	  aging	  hinder	  to	   define	   what	   differentiates	   normal	   brain	   senescence	   from	   the	   physiopathology	   leading	   to	  Alzheimer’s	  disease.	  Why	  the	  Aβ	  protein	  aggregates	  into	  senile	  plaques	  remains	  unclear	  and	  its	  link	  with	  the	  other	  pathological	  components	  of	  AD	  has	  not	  been	  elucidated.	  Although	  research	  has	   managed	   to	   highlight	   certain	   particularities	   of	   the	   physiopathology	   of	   the	   disease,	   post-­‐mortem	  measurements	   of	   the	   classic	   pathological	   hallmarks	   only	   explain	   to	   a	   limited	   extends	  the	  expression	  of	  dementia	  in	  the	  population	  and	  numerous	  other	  potentially	  modifiable	  factors	  also	  seem	  to	  contribute	  to	  the	  clinical	  presentation	  of	  dementia	  [84].	  Nevertheless	  we	  can	  agree	  on	  the	  fact	  that	  accumulation	  of	  β-­‐amyloid	  and	  pathological	  tau	  proteins	  as	  well	  as	  inflammatory	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processes	   take	   place	   in	   the	   pathogenesis	   of	   AD.	  What	   is	   not	  well	   defined	   is	   the	   link	   between	  these	  different	  components	  and	  the	  pathways	  leading	  to	  cell	  death	  and	  cognitive	  decline.	  Several	  assumptions	  and	  potential	  explanations	  have	  been	  proposed	  but	  it	  appears	  difficult	  to	  come	  to	  an	  agreement.	  For	  example	  Russo	  et	  al.	  showed	  that	  a	  variety	  of	  cytotoxic	  substances	  released	  by	   activated	   microglia	   might	   cause	   neuronal	   damage	   by	   enhancing	   oxidative	   stress	   and	  activating	   cell-­‐death	  pathways	   [48].	   They	   also	  highlighted	   that	   an	  over-­‐activation	  of	  microglia	  can	   result	   from	   a	   variety	   of	   injury	   signals,	   such	   as	   oxidative	   stress	   molecules,	   Aβ	   peptide,	  ischemia	   or	   brain	   trauma,	   which	   all	   promote	   erroneous	   signalling	   cascades	   and	   can	   induce	  proinflammatory	   cytokines	   production.	   However	   it	   has	   been	   suggested	   that	   increase	   in	   Aβ	  amounts	   may	   be	   also	   due	   to	   other	   processes.	   For	   example	   Lynch	   and	   his	   colleagues	   have	  speculated	  that	  AD	  pathogenetic	  cascade	  is	  not	  due	  to	  a	  single	  factor	  but	  to	  a	  collection	  of	  events,	  which	  accumulates	  with	  the	  already-­‐existing	  age-­‐related	  changes	  [50].	  	  	  Whatever	   initiates	   the	   pathological	   cascade,	   it	   appears	   from	   the	   similarity	   of	   their	   evolutions,	  that	   Aβ	   and	   GFAP	   are	   related	   and	   that	   they	   play	   a	   key	   role	   at	   the	   very	   beginning	   of	   the	  pathogenesis	  while	  both	  have	  their	  levels	  decrease	  with	  the	  progression	  of	  the	  disease	  and	  are	  not	  correlated	  with	  the	  worsening	  of	  the	  cognitive	  decline.	  These	  observations	  are	  in	  line	  with	  many	  experimental	  and	  epidemiological	  data	  from	  animal	  and	  cell	  culture	  models	  showing	  that	  Aβ	   deposits	   and	   activated	   glial	   cells	   can	  produce	   factors	   that	   are	   toxic	   for	  neurons	   and	   that	   a	  protective	  effect	  could	  be	  obtained	  only	  by	  a	  very	  early	  and	  prolonged	  used	  of	  anti-­‐inflammatory	  drugs	   [44,	   57,	   54].	   Thus	   the	   overproduction	   or	   decreased	   degradation	   of	   potentially	   toxic	  peptides	  such	  as	  Aβ	  and	  the	  subsequent	  activation	  of	  inflammatory	  processes	  may	  then	  just	  be	  initial	   steps	   in	   a	   long	   cascade	   of	   detrimental	   changes.	   This	   assumption	   is	   also	   supported	   by	  Eikelenboom	  et	   al.	  who	   showed	   that	   a	  neuroinflammatory	   response	   in	   the	   cerebral	  neocortex	  parallels	   the	   early	   stages	   of	   AD	   and	   precedes	   the	   late	   stage	   tau-­‐related	   pathology	   [77].	   As	  mentioned	   earlier,	   the	   presence	   of	   the	   tau	   pathological	   protein	   seems	  much	  more	   associated	  with	   the	   cognitive	   decline	   than	   the	   deposition	   of	   amyloid	   burden.	   Numerous	   articles	   of	   the	  current	  literature	  agree	  with	  this	  chronological	  order	  of	  the	  pathological	  cascade.	  For	  example,	  a	  study	   highlighted	   that	   whereas	   the	   degree	   of	   tauopathy	   correlates	   strongly	   with	   cognitive	  decline	  in	  AD,	  genetic,	  pathologic	  and	  biochemical	  evidence	  implicates	  the	  aggregation	  of	  Aβ	  as	  a	  critical,	   early	   trigger	   in	   the	   chain	   of	   events	   that	   leads	   to	   tauopathy,	   neuronal	   dysfunction	   and	  dementia	  [53].	  	  	  In	   conclusion	   although	   the	   physiopathological	   cascade	   leading	   to	   neuronal	   death	   and	   major	  cognitive	   decline	   that	   characterize	   Alzheimer’s	   disease	   is	   still	   not	  well	   understood,	   it	   appears	  that	  the	  hypothesis	  of	  inflammatory	  processes	  taking	  place	  at	  the	  beginning	  of	  the	  disease	  is	  an	  idea	  more	  and	  more	  accepted	  in	  the	  scientific	  community.	  More	  over	  a	  new	  emerging	  idea	  from	  recent	   research	   seems	   to	   indicate	   that	   therapies	   focused	   on	   inflammatory	   processes	   could	  provide	  a	  new	  therapeutic	  approach	  to	  the	  disease	  and	  that	  they	  should	  be	  administered	  as	  soon	  as	  possible	  when	  the	  symptoms	  are	  still	  mild	  or	  even	  not	  yet	  clinically	  detected.	  However,	   the	  results	  of	  these	  clinical	  trials	  have	  so	  far	  yielded	  only	  few	  conclusive	  results	  and	  still	  need	  to	  be	  further	   analysed. New	   diagnostic	   techniques	   are	   therefore	   required	   to	   detect	   the	   disease	   as	  early	  as	  possible.	  The	  understanding	  of	   the	  relationship	  of	   the	  pathological	  components	  of	   the	  disease	  still	  remains	  one	  of	  the	  major	  challenges	  of	  current	  research	  and	  appears	  as	  a	  necessity	  to	  help	  developing	  new-­‐targeted	  treatments.	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